# Journal of Medicinal Chemistry



Subscriber access provided by Nottingham Trent University

# Design, Synthesis and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68)

Xufen Yu, Xi-Ping Huang, Terry P. Kenakin, Samuel T. Slocum, Xin Chen, Michael L. Martini, Jing Liu, and Jian Jin

J. Med. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jmedchem.9b00869 • Publication Date (Web): 12 Jul 2019 Downloaded from pubs.acs.org on July 13, 2019

## Just Accepted

Article

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

# Design, Synthesis and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68)

Xufen Yu,<sup>†,#</sup> Xi-Ping Huang,<sup>‡,§,#,\*</sup> Terry P. Kenakin,<sup>‡</sup> Samuel T. Slocum,<sup>‡</sup> Xin Chen,<sup>†</sup> Michael L. Martini,<sup>†</sup> Jing Liu,<sup>†,\*</sup> and Jian Jin<sup>†,\*</sup>

<sup>†</sup>Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.

<sup>‡</sup>Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599

<sup>§</sup>The National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599

**ABSTRACT:** GPR68 is an understudied orphan G protein-coupled receptor (GPCR). It is expressed most abundantly in the brain, potentially playing important roles in learning and memory. Pharmacological studies with GPR68 have been hindered by lack of chemical tools that can selectively modulate its activity. We previously reported the first small-molecule positive allosteric modulator (PAM), ogerin (1), and showed that 1 can potentiate proton activity at the GPR68-G<sub>s</sub> pathway. Here, we report the first comprehensive structure-activity relationship (SAR) study on the scaffold of 1. Our lead compound resulted from this study, MS48107 (71), displayed 33-fold increased allosteric activity compared with 1. 71 demonstrated high selectivity over closely related proton GPCRs and 48 common drug targets, and was bioavailable and brain penetrant in mice. Thus, our SAR study has resulted in an improved GPR68 PAM for investigating the physiological and pathophysiological roles of GPR68 in vitro and in vivo.

## INTRODUCTION

GPR68 was originally discovered as a clinically related receptor in an ovarian cancer cell line as "OGR1" for ovarian cancer G protein-coupled receptor.<sup>1</sup> While it is widely expressed in most cells and tissues including spleen, testes, small intestine, peripheral blood leukocytes, heart, lung, placenta, kidney, and bone,<sup>1,2</sup> it is most abundantly expressed in the brain, particularly in the hippocampus<sup>3</sup> - the brain region that is critical for learning and memory. Despite being known for over two decades, GPR68 remains an understudied orphan GPCR according to IUPHAR.<sup>4</sup> Generally known as a proton-sensing GPCR, it couples to multiple signaling pathways through various G proteins (G<sub>s</sub>, G<sub>q</sub>, G<sub>i</sub>, and G<sub>12/13</sub>) in different cells.<sup>2,5–7</sup> However, it remains to be established whether GPR68 couples to the  $\beta$ -arrestin signaling pathway. Consistent with its capacity to couple to multiple signaling pathways and its wide expression pattern, GPR68 has been implicated in many biological processes, including pH homeostasis,<sup>2,8</sup> tumor growth and metastasis,<sup>6,7,9-11</sup> inflammation,<sup>12-14</sup> osteoclast development,<sup>9,15,16</sup> insulin secretion,<sup>17,18</sup> and epithelial barrier function.<sup>19,20</sup> Interestingly, the receptor also functions as a mechanotransducer that senses blood flow (shear stress) in arteries, thus modulating vascular physiology.<sup>21</sup> Thus, GPR68, a potentially important therapeutic target, is one of the National Institutes of Health (NIH)'s Illuminating the Druggable Genome (IDG) GPCRs.<sup>22</sup> Presently, the underlying molecular mechanisms have not been determined between proton-sensing and these physiological or pathological processes. Pharmacological studies of GPR68 have previously been hindered by the lack of small-molecule ligands. It is clear that potent and selective GPR68 ligands that can be used to activate or block its activity are urgently needed to elucidate GPR68 pharmacology and clarify its potential roles in the aforementioned biological processes.<sup>23</sup>

Previous studies have shown that receptor activity is reduced or completely lost if extracellular histidine residues are mutated, presumably by affecting protonation states responding to extracellular pH changes.<sup>2</sup> Therefore, it was proposed that alkaline pH conditions stabilize GPR68 in an inactive conformation by hydrogen bonding interactions involving extracellular histidine residues, while

acidification and histidine protonation breaks hydrogen bond interactions, initiating receptor activation.<sup>2</sup> The putative histidine binding sites for protons are scattered throughout different extracellular loops rendering challenges to directly activate or block this receptor with orthosteric ligands. This, in turn, makes allosteric binding site more attractive to target as with many other GPCRs.<sup>24,25</sup> Allosteric modulators rely on endogenous protons to produce function and can preserve the spatial and temporal nature of the proton-mediated activation of GPR68. Allosteric modulators bind to GPR68 at a site different from that of protons and function by fine-tuning proton activity through increasing or reducing proton affinity ( $\alpha$ -cooperativity), efficacy ( $\beta$ -cooperativity), or both.

For conventional GPCRs, such as metabotropic glutamate receptors (mGluRs), binding and functional assays can be carried out in biological systems that the concentration of the orthosteric ligand (i.e. glutamate) can be controlled. However, for GPR68, the orthosteric ligand is proton, which always presents in the receptor compartment. Therefore, the allosteric binding affinity ( $K_B$ ), defined as the dissociation equilibrium constant of allosteric modulator in the absence of orthosteric ligand (i.e. proton), does not have corresponding biological meaning and cannot be measured in binding assays. Instead, we can estimate the allosteric affinity cooperativity  $\alpha$ , efficacy cooperativity  $\beta$ , and allosteric binding affinity K<sub>B</sub> from functional assays according to the standard allosteric operational model.<sup>26–28</sup> The observed binding affinity of allosteric modulators can be calculated by the equation  $K_B =$  $(1+[A]/K_A)/(1+ \alpha[A]/K_A)$ , in which [A] is the proton concentration and K<sub>A</sub> is the equilibrium dissociation constant of protons at GPR68 in the absence of modulators. In structure-activity relationship (SAR) studies, we actually can optimize the potency of the modulators in proton-mediated signaling by optimizing  $\alpha$ ,  $\beta$  and/or K<sub>B</sub>. In contrast to traditional orthosteric agonists or antagonists which rely on binding affinity (K<sub>i</sub>) for selectivity, allosteric modulators achieve high selectivity through allosteric  $\alpha\beta$  cooperativity in addition to allosteric binding affinity (K<sub>B</sub>).<sup>29,30</sup> The overall allosteric activity can be quantified with a characteristic allosteric index,  $Log(\alpha\beta/K_B)$ ,<sup>31</sup> which contains

information about allosteric cooperativity and can be calculated and used as a guiding parameter for SAR studies and optimization.<sup>29,32</sup>

Development of small-molecule ligands for GPR68 remains a challenging task. A small number of isoxazole compounds have been reported to possess GPR68 agonist activity.<sup>33</sup> However, several reports suggested that the weak activity of isoxazoles could be non-specific.<sup>12,34</sup> Divalent metal ions, such as Cu<sup>2+</sup> and Zn<sup>2+</sup>, were initially used to inhibit GPR68 activity.<sup>2,19</sup> Recently, these divalent ions, in addition to Co<sup>2+</sup> and Mn<sup>2+</sup>, were reported to be GPR68 agonists.<sup>35–37</sup> However, these recent reports did not fully control pH, nor used a broad enough pH range to address potential allosteric mechanisms. In addition, Zn<sup>2+</sup> is a well-known allosteric modulator for the orphan receptor GPR39.<sup>38–40</sup> Moreover, these divalent ions are biologically-important metals or trace elements and play critical roles in many biological processes.<sup>41–43</sup> Therefore, these divalent metals are unlikely GPR68 selective tools.

In 2015, we reported the discovery of ogerin (1) as the first positive allosteric modulator (PAM) of GPR68.<sup>44</sup> Compound 1 potentiates proton activity in GPR68-mediated G<sub>s</sub>-cAMP production, but has no activity at related proton-sensing GPCRs, including GPR4 and GPR65. This selective ligand led to the discovery that GPR68 activation suppresses contextual- but not cue-dependent learning and memory, and does so in wild-type but not GPR68 knockout mice.<sup>44</sup> These data provide the first evidence for a role of GPR68 in cognition. Specifically, sustained hippocampal GPR68 activation may contribute to memory deficits. Compound 1, which is now commercially available, has been used by the research community and its PAM activity has been confirmed by other groups.<sup>21,45</sup> Compound 1 was identified from a ZINC sub-library of about 3.1 million compounds through a virtual screening campaign targeting GPR68.<sup>44,46</sup> Thorough SAR studies on the scaffold of compound 1 have not been reported to date. Here, we report a comprehensive SAR study at the following three regions of compound 1: (1) the aminotriazine core, (2) the benzyl alcohol moiety, and (3) the benzylamine moiety (Figure 1). We describe design, synthesis and biological characterization of various analogs. This study has resulted in the identification of significantly improved GPR68 PAMs.

## RESULTS

**Biological Assay and Data Analysis**. We used a GloSensor cAMP assay to characterize all of the synthesized putative GPR68 PAMs. More specifically, HEK293 T cells were transiently transfected with receptor and GloSensor cAMP plasmids for proton-mediated receptor activation of  $G_s$ -cAMP production. To determine allosteric modulator activity, proton concentration responses in the absence and presence of increasing concentrations of putative PAMs were quantified and results were analyzed using a standard allosteric operational model<sup>26–28</sup> in GraphPad Prism. Several previously reported compounds<sup>44</sup> (1, 20, 30, 55, 61, 62 and 63) were included in this study for comparison.

**Modifications of the Aminotriazine Core**. To investigate the SAR of the aminotriazine core, we replaced the free amino group on the triazine core with a few small alkylamino groups. We also switched the triazine core to a pyrimidine core (Scheme 1, Table 1). These designed compounds were prepared using the synthetic routes outlined in Scheme 1. Intermediates **4** and **9** were prepared according to the previously reported procedures<sup>44</sup> from 2,4,6-trichloro-1,3,5-triazine (**2**) and 2,6-dichlorpyrimidin-4-amine (**8**). Briefly, alkylamine substitution of one chloro group on trichlorotriazine **1** at low temperature provided alkylamino substituted dichlorotriazines **3**. Benzylamine substitution of one chloro group on dichlorotriazines **3** or dicholoropyrimidine **8** at an elevated temperature yielded intermediates **4** or **9**. Suzuki coupling between intermediates **4** or **9** and commercially available (2-(hydroxymethyl)phenyl)boronic acid provided the designed compounds, **5**–**7** and **10** (Scheme 1).<sup>44</sup>

As indicated in Table 1, a small mono-substituted amino group on the triazine core is well tolerated. Either methylamino (5) or ethylamino (6) group has a minimal effect on allosteric parameters or binding affinity. However, dimethyl amino group (7) completely eliminates the allosteric activity. Replacing the triazine core with a pyrimidine (10) also greatly reduces allosteric activity to barely detectable levels. These results suggest the amino substituted triazine core is critical for the PAM activity. Therefore, the aminotriazine core is maintained in the following SAR studies.

#### Journal of Medicinal Chemistry

Modifications of the Benzyl Alcohol Moiety. For the benzyl alcohol moiety, we explored a variety of substituents on the phenyl ring (Scheme 2, Table 2). The synthesis of these analogs started with 2-amino-4,6-dichloro-1,3,5-triazine (11). Benzylamine substitution of one chloro group on 11 provided the common intermediate 12. Suzuki coupling between intermediate 12 and a set of commercially available phenylboronic acids provided compounds 13–15, 21, 22-29 and 31-32 (Scheme 2A and 2D). Compound 16 was obtained by reducing acetophenone 15 (Scheme 2B). Compounds 18 and 19 were synthesized through reductive aminations of benzaldehyde 17 with different amines (Scheme 2C). Compounds 37 and 38 were prepared through Suzuki coupling between intermediate 12 and synthesized phenylboronic acids 36 bearing ethoxy and isopropoxy groups, respectively, followed by formal group reduction (Scheme 2E).

Switching the hydroxymethyl group (1) to hydrogen (13), methyl (14), methyl ketone (15), and 1-hydroxylethyl (16) groups is not tolerated and leads to either weak or inactive analogs. Replacing the hydroxymethyl group with an aminomethyl group (18) retains affinity cooperativity and efficacy cooperativity but with reduced allosteric binding affinity, rendering a less effective GPR68 PAM compared with 1. The N-methyl substituted aminomethyl (19) group further reduces allosteric activities and results in a weak PAM. Previously, we have demonstrated the importance of the position of the hydroxymethyl group: the ortho-hydroxymethyl isomer was much more effective than the metahydroxymethyl isomer to activate GPR68 G<sub>s</sub>-cAMP pathway.<sup>44</sup> We have confirmed this trend by retesting 20 and by comparing the activities of 1 and 20. This trend has also been confirmed by comparing the activities of 15 and 21 (two methyl ketone analogs). Based on these SAR results, we kept the ortho-positioned hydroxymethyl group in subsequent SAR studies and explored additional substituents, such as halides and alkoxy groups on the phenyl ring. First, we installed fluoro groups at 3-(22), 4-(23), 5-(24), and 6-(25) positions on the phenyl ring. Compared with 1, the 3-fluoro analog 22 is a less effective GPR68 PAM due to the decreased efficacy cooperativity and allosteric binding affinity. The 4-fluoro analog 23 shows slightly increased PAM activity compared with compound 1.

Interestingly, the 6-fluoro analog 25 has significantly improved affinity cooperativity (Log ( $\alpha$ ) = 1.15 ± 0.14). However, its binding affinity (-Log ( $K_B$ ) = 3.69 ± 0.12) is greatly reduced, resulting in an overall slightly worse PAM (Log( $\alpha\beta/K_B$ ) = 5.19 ± 0.03) than compound 1 (Log ( $\alpha\beta/K_B$ ) = 5.31 ± 0.05). The 5fluoro analog 24 is a slightly better PAM (Log ( $\alpha\beta/K_B$ ) = 5.69 ± 0.04) than 1 due to its slightly improved affinity cooperativity (Log ( $\alpha$ ) = 0.91 ± 0.07) and allosteric binding affinity (-Log (K<sub>B</sub>) = 4.58)  $\pm$  0.08). Next, we explored compounds with a chloro group at 4- (26), 5- (27), and 6- (28) positions on the phenyl ring. Similar to 25, all of these chloro analogs show improved affinity cooperativities (Log  $(\alpha) = 1.01 \pm 0.08$  (26);  $1.20 \pm 0.11$  (27); and  $1.25 \pm 0.19$  (28)). In addition, these compounds display improved allosteric binding affinities (-Log (K<sub>B</sub>) =  $4.76 \pm 0.14$  (26);  $4.49 \pm 0.19$  (27); and  $4.43 \pm 0.20$ (28)) albeit reduced efficacy cooperativities, resulting in slightly better PAMs (2- to 4-fold) than 1. We also explored analogs bearing a methoxy group at different substitution positions (29-32). A methoxy group in general leads to reduced allosteric index compared to 1. Among the four substitution positions, the 4-position (30) is more tolerated while the 6-position (32) shows least PAM activity. Consequently, we installed ethoxy (37) and isopropoxy (38) groups at the 4-postion to explore steric effects. The 4ethoxy group (37) slightly improves affinity cooperativity (Log ( $\alpha$ ) = 0.87 ± 0.11), maintains allosteric binding affinities, and slightly decreases efficacy cooperativity, resulting in a comparable allosteric index compared to 1. The 4-isopropoxy group (38) shows slightly improved allosteric activity  $(Log(\alpha\beta/K_B) = 5.74 \pm 0.07)$  compared to 1 due to the increased allosteric binding affinities (-Log (K<sub>B</sub>) =  $4.91 \pm 0.12$ ). These SAR results indicate that additional substituents on the benzyl alcohol moiety are tolerated, and appropriate substitutions on the phenyl ring could lead to enhanced allosteric activity. Several substituents were identified to improve the modulators' affinity cooperativities and/or allosteric binding affinities. However, none of the substituents increased the modulators' efficacy cooperativities.

**Modifications of the Benzylamine Moiety.** To evaluate the effects of the benzylamine moiety on allosteric activity, we designed a variety of compounds with differentially substituted benzylamines. In addition, we also explored different carbon linker length between the phenyl and amino groups

(Table 3). These compounds were prepared using  $SN_{Ar}$  and Suzuki coupling reactions described in Scheme 3.

Initially, a series of electron withdrawing groups (EWGs) such as fluoro (41 - 43), chloro (44 - 43)46), and trifluoromethyl (47 - 49) were introduced to the phenyl moiety to explore their effects at different substitution positions. 2-, 3- and 4-fluoro groups lead to slightly improved allosteric indexes mainly due to the increased affinity cooperativity with Log ( $\alpha$ ) values at 0.98 ± 0.15, 0.70 ± 0.13, and  $1.09 \pm 0.30$ , respectively. Compared with the fluoro substitutions, the chloro substitutions provide more significant allosteric activity improvement because of the higher allosteric binding affinities ((-Log (K<sub>B</sub>)  $= 5.07 \pm 0.08$  (44),  $4.97 \pm 0.19$  (45), and  $5.22 \pm 0.07$  (46)). Similarly, the trifluoromethyl analogs show improved allosteric index due to improved allosteric binding affinities ((-Log ( $K_B$ ) = 5.05 ± 0.10 (47),  $5.11 \pm 0.12$  (48), and  $5.03 \pm 0.08$  (49)). Thus, EWGs are able to improve the modulators' allosteric activities by increased affinity cooperativities or allosteric binding affinities. However, the substitution positions only have moderate effects on the allosteric indexes. Next, we explored a couple of electron donating groups (EDGs): methyl (50 - 52) and methoxy (52 - 55). The methyl analogs show slightly improved allosteric indexes mainly due to slightly higher allosteric binding affinity (50) or affinity cooperativity (51 and 52). Although the 2-, 3- and 4-methoxy groups improve the affinity cooperativities (Log ( $\alpha$ ) = 0.98 ± 0.17 (53), 0.89 ± 0.18 (54), and 0.78 ± 0.11 (55)), they reduce the allosteric binding affinities, resulting in analogs with reduced allosteric indexes. We subsequently explored a few larger alkoxy groups, such as ethoxy (56), isopropoxy (57), cyclopropoxy (58), and phenoxy (59), at the 4-postion. Interestingly, most of these larger ether substituents diminish the efficacy cooperativities, leading to GPR68 α-PAMs, positive allosteric modulators with affinity cooperativities ( $\alpha$ ) greater than 1 and efficacy cooperativities ( $\beta$ ) equals or is close to 1. Compared with 4-methoxy group (55), these larger alkoxy groups enhance allosteric binding affinities ((-Log ( $K_B$ ) =  $4.77 \pm 0.03$  (56),  $4.99 \pm 0.09$  (57),  $5.07 \pm 0.12$  (58), and  $5.19 \pm 0.14$  (59)), leading to improved allosteric activities. In particular, the 4-phenoxy analog (59) is an  $\alpha$ -PAM with the most improved allosteric

activity compared to compound **1**. Previously, we have shown that longer carbon linkers between the phenyl and amino groups resulted in analogs with higher PAM activity.<sup>44</sup> We have now confirmed this SAR trend by testing compounds **60** – **63**. While a shorter linker (**60**) results in reduced an allosteric index mainly due to the reduced allosteric binding affinity ((-Log (K<sub>B</sub>) =  $3.92 \pm 0.10$  (**60**)), longer linkers (**61** – **63**) enhance allosteric binding affinities ((-Log (K<sub>B</sub>) =  $4.50 \pm 0.21$  (**61**),  $5.22 \pm 0.04$  (**62**), and  $5.52 \pm 0.12$  (**63**)), leading to improved allosteric indexes. We also extended the carbon linker length of the 4-phenoxy substituted benzylamine analog **59**, leading to three analogs **64** – **66**. These analogs, however, do not show enhanced allosteric activities compared to **59**. Instead, longer linkers lead to reduced allosteric activities. Interestingly, these analogs all retain high affinity cooperativity  $\alpha$  values. Thus, extending the carbon linker length between the phenyl group and amino group does not always lead to better PAMs. Importantly, these SAR results suggest that, similar to the benzyl alcohol moiety, modifications of the benzylamine moiety could improve the modulators' affinity cooperativities and/or allosteric binding affinities, but not their efficacy cooperativities.

Combined Modifications of Different Moieties. The SAR study described above indicates that several functional groups, such as 6-fluoro (25) and 5-chloro (27) substituted hydroxymethylphenyl moieties and 2-fluoro (41), 4-fluoro (43), 3-methyl (51), 2-methoxy (53), and 4-phenoxy (59) substituted benzylamine, lead to high affinity cooperativities and/or improved allosteric binding affinities. Using these preferred moieties, we designed a number of combination compounds, to further improve the allosteric activity and obtain potent GPR68  $\alpha$ -PAMs. We also explored different linker length between the phenyl group and amino group (n = 1-4). Synthesis of these compounds is summarized in Scheme 3 and SAR results of these compounds are summarized in Table 4.

Compared to 25, 2-fluoro (67), 4-fluoro (68), 3-methyl (69), 2-methoxy (70), and 4-phenoxy (71) substituted benzyl groups retain relatively high affinity cooperativity values and show low efficacy cooperativity values. Most strikingly, the 4-phenoxy analog 71 displays greatly enhanced allosteric binding affinity (-Log ( $K_B$ ) = 5.85 ± 0.12 versus 3.69 ± 0.12 for compound 25), resulting in a very

#### Journal of Medicinal Chemistry

potent GPR68  $\alpha$ -PAM. Compared with 1, compound 71 has 33-fold better allosteric activity  $(\text{Log}(\alpha\beta/\text{K}_B) = 6.83 \pm 0.08 \text{ versus } 5.31 \pm 0.05 \text{ for compound } 1)$ . We have shown that the linker length between the phenyl and amino groups has different effects on the allosteric activities, depending on different R<sup>5</sup> groups (60 – 63 and 59, 64 – 65 (see above)). Extending the carbon linker length of 25 to 2 – 4 results in compounds 72 – 74. Compared with 25, all of these longer linker analogs maintain high affinity cooperativity values and show low efficacy cooperativity values. For allosteric binding affinity, the 2-carbon linker (72, -Log (K<sub>B</sub>) = 5.04 ± 0.09) is optimal among the 4 linker lengths explored. Extending the carbon linker length of 71 to 2 – 3 leads to  $\alpha$ -PAMs 75 and 76 with retained high affinity cooperativities, low efficacy cooperativities, but reduced allosteric binding affinities.

To improve the allosteric activity of 27, we also increased the linker length between the phenyl group and the amino group. The longer linker analogs 77 - 79 maintain high affinity cooperativities and low efficacy cooperativities, and enhance allosteric binding affinities (-Log (K<sub>B</sub>) = 5.14 ± 0.11 (77), 5.35 ± 0.06 (78), and 4.98 ± 0.10 (79)) with the 3-carbon linker (78) being optimal. Lastly, we replaced the benzylamine moiety of 27 with a 4-phenoxy substituted benzylamine moiety (80) or a 4-phenoxy substituted homobenzylamine moiety (81). Compounds 80 and 81 preserve the α-PAM activity. Compared with 27, both compounds show similar allosteric binding affinities (-Log (K<sub>B</sub>) = 4.70 ± 0.14 (80), and 4.59 ± 0.18 (81)) and similar overall allosteric activities (i.e., Log(αβ/K<sub>B</sub>) values).

Our SAR study has identified several GPR68 PAMs with better allosteric activities than compound 1. For example, 46, an  $\alpha\beta$ -PAM ( $\alpha$  and  $\beta > 1$ ), has shown 6-fold higher allosteric activity (Log( $\alpha\beta/K_B$ ) value) than 1.  $\alpha$ -PAM 71 has the highest Log( $\alpha\beta/K_B$ ) value, which is 33-fold higher than that of 1. Compounds 77 and 78,  $\alpha$ -PAMs, have approximately 10-fold better allosteric activity than 1. We selected these four GPR68 PAMs for further characterization.

Selectivity Profiles of Selected GPR68 PAMs. To determine selectivity of 46, 71, 77, and 78 for GPR68 over other closely related proton GPCRs, such as GPR4 and GPR65, we tested these GPR68 PAMs against GPR4 and GPR65 using GloSensor cAMP assays. As shown in Figure 2A-2D, GPR4 and ACS Paragon Plus Environment GPR65 have different response profiles to proton stimulation as compared to GPR68 in the absence of modulators. The proton potency values (pEC<sub>50</sub>) were pH 8.04 (hill slope of 5.25) for GPR4, pH 7.47 (hill slope of 4.57) for GPR65, and pH 6.73 (hill slope of 3.38) for GPR68. In the presence of the lead PAM **71** (Figure 2B) as well as **1** (Figure 2A), proton activity at GPR68 is potentiated in a PAM concentration-dependent manner (proton concentration response curves were shifted leftward (affinity cooperativity  $\alpha$ >1) and upward (efficacy cooperativity  $\beta$ >1)), while compound **71** has no PAM activity at GPR4 (Figure 2C) and weak potentiation of proton activity at GPR65 only at high concentrations (Figure 2D). These data indicate that our lead PAM **71** is selective for GPR68 over the functionally related receptors GPR4 and GPR65. Similarly, as illustrated in Supplementary Figure 2, compounds **46**, **77**, and **78** show no effect or weak activity only at high concentrations at GPR4 and GPR65.

Compounds **46**, **71**, **77**, and **78** were further screened in radioligand binding assays against a panel of 48 common drug targets, including GPCRs, neurotransmitter transporters, and hERG ion channels. As indicated in Figure 2E and Supplementary Figure 3, most of these compounds have affinity values higher than 300 nM (pK<sub>i</sub> = 6.50) at all targets tested. Among the tested GPCRs, 5-HT<sub>2B</sub> has moderate binding affinity (pK<sub>i</sub> = 6.50 - 7.00) to **71**, **77**, and **78**, with K<sub>i</sub> values of 219 nM, 209 nM, and 295 nM respectively. In addition, adenosine 2A (A<sub>2A</sub>) receptor has moderate binding affinity to **46** with K<sub>i</sub> value of 300 nM. The compounds with binding affinities between 300 – 100 nM (pK<sub>i</sub> = 6.50 - 7.00) were further tested in functional assays to determine if they acted as agonists or antagonists. At 5-HT<sub>2B</sub> receptors, **71**, **77**, and **78** show no agonist activity but display weak antagonist activity (Supplementary Figure 4A and 4B) with functional affinity (K<sub>i</sub>) values of 310 nM, 678 nM, and 212 nM, respectively, which are comparable to their corresponding binding affinities. At A<sub>2A</sub> receptors (Supplementary Figure 4C), **46** displays no agonist activity, but shows weak inverse agonist activity with functional affinity of 6,700 nM.

#### Journal of Medicinal Chemistry

For lead PAMs with the potential to serve as molecular probes for chemical biology studies, it is also desirable to determine their off-target agonist activities at other human GPCRs. Therefore, **46**, **71**, **77**, and **78** were tested against all human GPCRome in our PRESTO-Tango screening assays.<sup>47</sup> As illustrated in Figure 2F, across the whole human GPCRome, compound **71** has agonist activity only at the MT<sub>1</sub> and MT<sub>2</sub> receptors. Compound **46** shows no agonist activity while compounds **77** and **78** display agonist activity at an atypical chemokine receptor 3 (ACKR3) (previously known as CXCR7)<sup>48,49</sup> (Supplementary Figure 5). Subsequent concentration response assays indicate that **71** is a weak full agonist at the MT<sub>1</sub> receptor (EC<sub>50</sub> = 320 nM) and a weak partial agonist activity at the MT<sub>2</sub> receptor (EC<sub>50</sub> = 540 nM; E<sub>max</sub> = 24%) (Supplementary Figure 6). Consistently, **71** displays low binding affinities to MT<sub>1</sub> (5,900 nM) and MT<sub>2</sub> (1,100 nM) receptors. Compounds **77** and **78** show full agonist activities at ACKR3 with EC<sub>50</sub> values of 1,700 nM and 690 nM, respectively (Supplementary Figure 6).

**Characterization of Selected Lead Modulators at Mouse GPR68.** To assess whether selected human GPR68 PAMs also function as PAMs at mouse GPR68 receptor, we determined the PAM activity at mouse GPR68 in the absence and presence of lead modulators for proton mediated  $G_s$ -cAMP production. As illustrated in Figure 3 and Supplementary Figure 7, in the absence of modulators, mouse GPR68 responds to proton stimulation in a very similar way as human GPR68 with a potency of pH 6.68 (hill slope of 2.95). As with human GPR68, the proton activity at mouse GPR68 is also potentiated by the lead PAMs **71** (Figure 3), **46**, **77** and **78** (Supplementary Figure 7) in a concentration dependent manner – shifting proton response curves to the left with increased maxima. Extracted allosteric parameters determined by fitting the curves to the operational allosteric model are listed in Table 5. Compared with the allosteric activity of these PAMs at human GPCR68, the compound display 2 – 3-fold less allosteric activity at mouse GPR68, suggesting a potential small species difference in sensitivity to GPR68 PAMs.

In Vivo Pharmacokinetic Properties of Compound 71. After obtaining the promising in vitro potency and selectivity results for compound 71, we assessed in vivo pharmacokinetic properties of this

lead compound in mice. Since GPR68 is most abundantly expressed in the brain and is associated with learning and memory, it is necessary to test whether this compound can penetrate the blood-brain barrier (BBB) in animals. A single intraperitoneal injection at the dose of 25 mg/kg led to high exposure levels (above 10  $\mu$ M) in both plasma and brain at 0.5 h in mice (Figure 4). The high compound exposure levels in both plasma and brain were maintained for 2 h. These results have demonstrated that compound **71** is bioavailable and can readily cross the BBB in mice. Furthermore, there were no clinical signs observed in test mice. Taken together, these results suggest that compound **71** is a valuable chemical tool for investigating biological function of GPR68 in vivo.

Characterization of Selected Inactive Analogs. Compounds 7, 20 (a known inactive analog of 1)<sup>44</sup> and 21 do not show PAM activity at GPR68, GPR4, and/or GPR65 (Supplementary Figures 1, 2). There are two possible mechanisms for the lack of apparent PAM activity by these compounds in functional assays: they do not bind GPR68, or they bind but function as silent allosteric modulators (SAMs, with  $\alpha = 1$  and  $\beta = 1$ ). Such allosteric modulators have been described as molecules that bind to the allosteric site without producing cooperative activity on the agonist<sup>50</sup> for opioid receptors<sup>51,52</sup> and mGLuR5 receptors<sup>53</sup>. Functional assays can potentially differentiate the lack of binding from silent allosteric modulation as the latter can be detected through interference with the observed PAM activity. We therefore tested the effects of these apparently inactive analogs (at 10  $\mu$ M) on the positive allosteric activity of 71 (0.3 µM). As shown in Supplementary Figure 8, proton responses are left shifted by 71 as expected and are minimally affected by the presence of the inactive analogs, suggesting that the inactive analogs do not bind to the allosteric site of GPR68 to antagonize the PAM activity of 71. In addition, inactive analogs 7 and 21 show minimal binding affinities to common drug targets (Supplementary Figure 3). Moreover, 7 and 21 display no off-target agonist activity across the human GPCRome (Supplementary Figure 5). Therefore, compounds 7, 20, and 21 are potentially useful inactive controls for studying GPR68 pharmacology.

## DISCUSSIONS AND CONCLUSIONS

#### Journal of Medicinal Chemistry

It is worth to note the unique nature of GPR68 pharmacology as the co-binding ligand for the allosteric effect, namely hydrogen ion, is always present. Therefore, GPR68 allosteric modulators will likely have direct consequences to cellular signaling: PAMs will produce direct agonism while negative allosteric modulators (NAMs) will produce inverse agonism. In addition, differences exist for PAMs depending on whether the allosterism primarily affects affinity ( $\alpha$ -effect) or efficacy ( $\beta$ -effect). Specifically,  $\alpha$ -PAMs ( $\alpha > 1$  and  $\beta \approx 1$ ) will produce greater agonism at neutral pH conditions while  $\beta$ -PAMs ( $\alpha \approx 1$  and  $\beta > 1$ ) will produce relatively more agonism in acidic environments. The differences in signaling produced by  $\alpha$ - versus  $\beta$ -modulators are described in detail in the Supporting Information. In the present study, we are able to achieve potent and selective GPR68  $\alpha$ -PAMs (e.g., compound **46**), but not  $\beta$ -PAMs.

There are examples that precipitous changes in allosteric activity may come from apparently small changes in molecular structure, known specifically as 'activity switching' in the PAMs for mGluRs.<sup>54–56</sup> In this SAR study, with compound **1** as a scaffold, we also observed large changes in allosteric activity (from active PAMs to inactive analogs) with small structural modifications to the aminotriazine core and benzylalcohol group. Further SAR and mutational studies are needed to elucidate underlying molecular mechanisms, which will aid in designing better modulators.

Depending on the pK<sub>a</sub> values, the physiochemical properties of modulators, such as net charges and H-bonding potential, could change under different pH conditions. Correspondingly, binding interactions of modulators with GPR68 could be pH dependent, leading to different levels of receptor activation in both a pH and concentration dependent manner. Therefore, our functional assay is designed to use a wide pH range and is done in the absence and presence of increasing concentrations of modulators to generate at least 6 sets of 16-point proton concentration response curves (each in quadruplicate) in a single 384-well plate for proper comparison.

To achieve novel brain penetrant GPR68 PAMs, we tried to maintain low tPSA values by utilizing lipophilic substituents on the triazine scaffold. While this strategy successfully led to BBB ACS Paragon Plus Environment

permeable compound **71**, these lipophilic groups could also reduce the aqueous solubility of the compounds. Indeed, we have observed bell-shaped proton concentration-response curves at high compound concentrations (10 and/or 30  $\mu$ M) for compounds **57** – **59**, **63** – **66**, **75** – **78**, and **81**. The assay signals waned when modulators were tested at pH conditions below pH 7.40. This is likely due to the reduced aqueous solubility of these compounds under acidic conditions or aggregation.<sup>57,58</sup> Addition of 1 mg/mL BSA in assay buffers may have improved solubility but did not affect the bell-shaped curves. Under these circumstances, we may have slightly underestimated the allosteric parameters of these compounds, especially with regard to the efficacy cooperativity  $\beta$ . In any case, this effect prevented high concentrations of modulators from being included in the functional assays. This, in turn, prevented observation of the characteristic saturation (termed the "ceiling effect") of allosteric modulation, further leading to increased levels of variation in estimated allosteric parameters.

In summary, we have performed a comprehensive SAR study by exploring three regions of the scaffold represented by compound **1**. While structural changes on the aminotriazine core did not improve the allosteric activity, modifications to the benzylalcohol and benzylamino groups did lead to slightly more active GPR68 PAMs with increased affinity cooperativities and allosteric binding affinities. The subsequently designed combination compounds with the substituents showing best  $\alpha$  and K<sub>B</sub> values from each region ultimately resulted in much improved GPR68  $\alpha$ -PAMs including compound **71**, which has 33-fold increased allosteric activity compared with **1**. We also identified a significantly improved  $\alpha\beta$ -PAM, compound **46**. We further determined that compounds **71** and **46** and two additional GPR68 PAMs were selective for GPR68 over GPR4 and GPR65, two closely related proton GPCRs. In addition, these four compounds had no or low off-target agonist activity across the human GPCRome, and had weak to moderate binding affinity to 48 common GPCRs, ion channels and transporters. Moreover, we demonstrated that our lead compound, **71**, is bioavailable in mice and has excellent brain penetration. Last, we identified several potentially useful inactive controls. These novel GPR68 PAMs and inactive controls are valuable chemical tools for studying GPR68 biology and pharmacology.

 Furthermore, our study paved the way for developing the next generation of GPR68 PAMs and allosteric modulators for other GPCRs.

#### **EXPERIMENTAL SECTION**

Chemistry General Procedures. All chemical reagents were purchased from commercial vendors and used without further purification. Dry solvents were purchased from commercial vendors with a verified anhydrous standard. Microwave-heated reactions were performed with a Discover SP microwave system with an Explorer 12 Hybrid Autosampler by CEM (Buckingham, UK). EMD Milipore 210-270 um 60-F254 silica gel plates were used to perform analytical thin-layer chromatography (TLC). The plates were examined under a UV Lamp. The flash column chromatography was conducted using a Teledyne ISCO CombiFlash Rf<sup>+</sup> instrument. This instrument was also equipped with a variable wavelength UV detector and a fraction collector. RediSep Rf normal phase silica columns were used for purification. Preparative high-performance liquid chromatography (HPLC) was used to purify all final compounds. HPLC was conducted on an Agilent Prep 1200 series with the UV detector set to 254 nm. Samples were injected into a Phenomenex Luna 750 x 30 mm, 5 um C18 column. Separation was performed at room temperature with a flow rate of 40 mL/min. The linear gradient program was set as follows: 10% of methanol (A) in H<sub>2</sub>O containing 0.1% TFA (B) to 100% of methanol (A). All compounds for biological evaluation were determined to have > 95% purity after the purification using the aforementioned prep-HPLC methods. An Agilent 1200 series system with DAD detector and a 2.1 mm x 150 mm Zorbax 300SB-C18 5 µm column for chromatography were used to obtain HPLC spectra for all compounds. Samples (0.5 µL) were injected onto a C18 column at room temperature. The column flow rate was set to 0.4 mL/min. Chromatography was performed with water containing 0.1% formic acid as Solvent A and acetonitrile containing 0.1% formic acid as solvent B. The linear gradient was set as follows: 1% B (0-1 min), 1-99% B (1-4 min), and 99% B (4-8 min). An Agilent G1969A API-TOF with an electrospray ionization (ESI) source was used to acquire high-resolution mass spectra (HRMS) data in positive ion mode. All compounds were also characterized using a Bruker (Billerica,

MA) DRX-600 Nuclear Magnetic Resonance (NMR) spectrometer (600 MHz, <sup>1</sup>H-NMR). Chemical shifts are reported in parts per million (ppm,  $\delta$ ) relative to residual solvent peaks. <sup>1</sup>H-NMR data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant, and integration.

#### General Procedures for Preparation of Compounds 5-7.

(2-(4-(Benzylamino)-6-(methylamino)-1,3,5-triazin-2-yl)phenyl)methanol (5)<sup>59</sup>. Intermediate 3 was prepared according to previously published procedures starting with 4,6-dichloro-*N*-methyl-1,3,5-triazin-2-amine (2) and benzylamine. The white solid 3 (24.9 mg, 0.1 mmol) was suspended in dioxane (0.8 mL) and water (0.2 mL) in a microwave tube. Then, tetrakis(triphenylphosphine)palladium (0) (5.8 mg, 5 mol %), potassium carbonate (27.6 mg, 0.2 mmol), and (2-(hydroxymethyl)phenyl)boronic acid (30.4 mg, 0.2 mmol)) were added. The mixture was heated to 120 °C for 20 min under microwave irradiation. The resulting mixture was filtered through Celite with ethyl acetate as eluent solvent. The filter was washed with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting residue was dissolved in 1.5 mL of methanol and purified by preparative HPLC to yield 7 as white solid (27 mg, 84%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.81 (d, *J* = 7.8 Hz, 1H), 7.60 (dd, *J* = 20.0, 7.4 Hz, 3H), 7.50 (t, *J* = 7.6 Hz, 1H), 7.43 (d, *J* = 7.6 Hz, 1H), 7.35 (t, *J* = 7.8 Hz, 2H), 7.31 – 7.24 (m, 1H), 4.81 (s, 2H), 4.72 (d, *J* = 5.1 Hz, 2H), 3.05 (d, *J* = 5.3 Hz, 3H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sup>+</sup> 322.1662, found 322.1678.

(2-(4-(Benzylamino)-6-(ethylamino)-1,3,5-triazin-2-yl)phenyl)methanol (6). White solid (15.2 mg, 98%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (d, *J* = 7.8 Hz, 1H), 7.69 – 7.57 (m, 2H), 7.51 (t, *J* = 7.6 Hz, 1H), 7.35 (ddt, *J* = 41.4, 34.0, 7.3 Hz, 5H), 4.81 (s, 2H), 4.70 (s, 2H), 3.54 (q, *J* = 7.2 Hz, 2H), 1.22 (t, *J* = 7.2 Hz, 3H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sup>+</sup> 336.1819, found 336.1873.

(2-(4-(Benzylamino)-6-(dimethylamino)-1,3,5-triazin-2-yl)phenyl)methanol (7). White solid (32 mg,

42%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.90 (d, *J* = 7.8 Hz, 1H), 7.62 (dd, *J* = 24.7, 7.5 Hz, 2H), 7.52 (t, *J* = 7.6 Hz, 1H), 7.42 (d, *J* = 7.5 Hz, 2H), 7.35 (t, *J* = 7.4 Hz, 2H), 7.28 (t, *J* = 7.3 Hz, 1H), 4.84 (s, 2H), 4.70 (s, 2H), 3.32 (d, *J* = 24.3 Hz, 6H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sup>+</sup> 336.1819, found 336.1832.

(2-(6-Amino-2-(benzylamino)pyrimidin-4-yl)phenyl)methanol (10). Compound 10 was synthesized following the same procedure for preparing 5 starting with 2,6-dichloropyrimidin-4-amine 8 and benzylamine. The title compound 10 was obtained as white solid (27.2 mg, 92%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.57 (d, *J* = 5.2 Hz, 2H), 7.53 – 7.43 (m, 2H), 7.39 (d, *J* = 7.6 Hz, 2H), 7.34 (t, *J* = 7.6 Hz, 2H), 7.27 (t, *J* = 7.3 Hz, 1H), 6.20 (s, 1H), 4.66 (s, 2H), 4.62 (s, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>19</sub>N<sub>4</sub>O<sup>+</sup> 307.1553, found 307.1542.

### General Procedures for Preparation of Compounds 13-15.

Intermediate 12 was prepared according to previously published procedures<sup>44</sup>.

N<sup>2</sup>-benzvl-6-phenvl-1,3,5-triazine-2,4-diamine (13). To a dried microwave tube was added, intermediate (23.6 mg. 0.1 mmol), phenylboronic acid (24.4 mg. 0.2 mmol). tetrakis(triphenylphosphine)palladium (5.8 mg, 5 mol %), potassium carbonate (27.6 mg, 0.2 mmol) dioxane (0.8 mL) and water (0.2 mL). The mixture was heated to 120 °C for 20 min under microwave irradiation. The resulting mixture was filtered through Celite with ethyl acetate as eluent solvent. The filter was washed with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting residue was dissolved in 1.5 mL of methanol and purified by preparative HPLC to yield 13 as white solid (26 mg, 94%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) δ 8.15 (t, *J* = 6.3 Hz, 2H), 7.69 (q, *J* = 8.9, 8.2 Hz, 1H), 7.57 (dt, J = 11.2, 7.5 Hz, 2H), 7.42 – 7.30 (m, 4H), 7.27 (g, J = 6.9 Hz, 1H), 4.69 (d, J = 3.8 Hz, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>16</sub>N<sub>5</sub><sup>+</sup> 278.1400, found 278.1415.

N<sup>2</sup>-benzyl-6-(o-tolyl)-1,3,5-triazine-2,4-diamine (14). White solid (29 mg, 98%). <sup>1</sup>H NMR (600 MHz,

CD<sub>3</sub>OD)  $\delta$  7.60 (dd, J = 12.1, 7.8 Hz, 1H), 7.51 (t, J = 7.6 Hz, 1H), 7.43 – 7.31 (m, 6H), 7.28 (q, J = 7.2, 5.7 Hz, 1H), 4.69 (s, 2H), 2.52 (s, 3H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>18</sub>N<sub>5</sub><sup>+</sup> 292.1557, found 292.1539.

**1-(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)phenyl)ethan-1-one (15)**. White solid (48 mg, 54%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  8.06 (d, *J* = 7.7 Hz, 1H), 7.89 (t, *J* = 7.9 Hz, 1H), 7.80 (dd, *J* = 7.7, 3.2 Hz, 1H), 7.73 (dt, *J* = 11.0, 7.6 Hz, 1H), 7.44 – 7.23 (m, 5H), 4.71 (s, 2H), 2.01 (d, *J* = 2.4 Hz, 3H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>18</sub>N<sub>5</sub>O<sup>+</sup> 320.1506, found 320.1531.

**1-(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)phenyl)ethan-1-ol (16)**. Compound **15** (15 mg, 0.05 mmol) was dissolved in THF (mL). After the mixture was cooled to 0 °C, sodium borohydride (4 mg, 0.1 mmol) was added slowly. The reaction was monitored by TLC till **15** disappeared. Methanol (1 mL) was added slowly to quench the reaction. The mixture was filtered, and concentrated *in vacuo*. The resulting residue was dissolved in 1.5 mL of methanol and purified by preparative HPLC to yield **16** as white solid (16 mg, 51%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.76 – 7.59 (m, 3H), 7.52 – 7.44 (m, 2H), 7.43 – 7.31 (m, 4H), 7.28 (dd, *J* = 9.2, 5.7 Hz, 1H), 5.27 – 5.18 (m, 1H), 4.70 (s, 2H), 1.53 (d, *J* = 6.5 Hz, 3H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sup>+</sup> 322.1662, found 322.1669.

**6-(2-(Aminomethyl)phenyl)**-N<sup>2</sup>-benzyl-1,3,5-triazine-2,4-diamine (18). Intermediate 17 (123 mg, 86%) was prepared following the same procedures that were used to prepare 13 starting with 2-formylphenyl boronic acid and intermediate 12. To a suspension of intermediate 17 (47 mg, 0.15 mmol), magnesium sulfate (200 mg) and NH<sub>3</sub>:H<sub>2</sub>O (0.75 mmol, 107  $\mu$ L) in THF (2 mL) was added sodium borohydride (5.7 mg, 0.15 mmol) slowly. After stirring for 2 d at room temperature, methanol (1 mL) was added slowly to quench the reaction. The mixture was filtered, and concentrated *in vacuo*. The resulting residue was dissolved in 1.5 mL of methanol and purified by preparative HPLC to yield **18** as yellow oil (21 mg, 45%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (d, *J* = 7.8 Hz, 1H), 7.64 (t, *J* = 7.5 Hz, 1H), 7.51 (q, *J* = 7.0, 6.5 Hz, 1H), 7.40 (d, *J* = 7.6 Hz, 1H), 7.37 – 7.31 (m, 3H), 7.29 (q, *J* = 7.9, 7.2 Hz, 1H), 4.82 (s, 2H), 4.69 (s, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for ACS Paragon Plus Environment

 $C_{17}H_{19}N_6^+$  307.1666, found 307.1676.

N<sup>2</sup>-benzyl-6-(2-((methylamino)methyl)phenyl)-1,3,5-triazine-2,4-diamine (19). Compound 19 was prepared following the general procedure for preparing compound 18 from intermediate 17 and methylamine (2 M in THF). Yellow oil (22 mg, 67%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) δ 7.69 (dd, J = 7.6, 3.7 Hz, 1H), 7.66 – 7.49 (m, 3H), 7.39 – 7.15 (m, 5H), 4.62 (s, 2H), 4.39 (s, 2H), 2.79 (s, 3H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>21</sub>N<sub>6</sub><sup>+</sup> 321.1882, found 321.1877.

## General Procedures for Preparation of Compounds 21-29 and 31-32.

Compounds 21-19 and 31-32 were prepared following the general procedure for preparing compound 13 from intermediate 12 and commercially available substituted phenylbronic acids.

**1-(3-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)phenyl)ethan-1-one (21)**. White solid (28 mg, 87%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  8.80 (s, 1H), 8.44 (d, *J* = 7.8 Hz, 1H), 8.32 – 8.20 (m, 1H), 7.78 – 7.63 (m, 1H), 7.47 – 7.19 (m, 5H), 4.69 (s, 2H), 2.67 (s, 3H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>18</sub>N<sub>5</sub>O<sup>+</sup> 320.1506, found 320.1522.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-6-fluorophenyl)methanol (22). White solid (29 mg, 89%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.63 (d, *J* = 7.8 Hz, 1H), 7.53 (td, *J* = 8.0, 5.1 Hz, 1H), 7.44 – 7.32 (m, 5H), 7.28 (t, *J* = 7.5 Hz, 1H), 4.83 (s, 2H), 4.69 (s, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>FN<sub>5</sub>O<sup>+</sup> 326.1412, found 326.1435.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-5-fluorophenyl)methanol (23). White solid (30 mg, 91%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.86 (dt, J = 10.6, 5.3 Hz, 1H), 7.43 – 7.30 (m, 5H), 7.30 – 7.15 (m, 2H), 4.84 (d, J = 5.1 Hz, 2H), 4.67 (d, J = 5.0 Hz, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>FN<sub>5</sub>O<sup>+</sup> 326.1412, found 326.1426.

**(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-4-fluorophenyl)methanol (24)**. White solid (28 mg, 86%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) δ 7.66 – 7.57 (m, 2H), 7.42 – 7.31 (m, 5H), 7.30 – 7.24 (m, 1H),

4.78 (s, 2H), 4.69 (s, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>FN<sub>5</sub>O<sup>+</sup> 326.1412, found 326.1407.

**(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (25)**. White solid (31 mg, 94%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) δ 7.63 – 7.54 (m, 2H), 7.43 – 7.31 (m, 5H), 7.28 – 7.23 (m, 1H), 4.76 (s, 2H), 4.69 (s, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>FN<sub>5</sub>O<sup>+</sup> 326.1412, found 326.1419.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-5-chlorophenyl)methanol (26). White solid (16 mg, 64%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.81 (dd, J = 8.4, 2.0 Hz, 1H), 7.65 (s, 1H), 7.48 (dd, J = 21.4, 8.4 Hz, 1H), 7.41 – 7.30 (m, 4H), 7.27 (t, J = 7.5 Hz, 1H), 4.81 (s, 2H), 4.68 (s, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>ClN<sub>5</sub>O<sup>+</sup> 342.1116, found 342.1111.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-4-chlorophenyl)methanol (27). White solid (27 mg, 93%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.86 (d, J = 2.3 Hz, 1H), 7.65 – 7.56 (m, 2H), 7.42 – 7.32 (m, 4H), 7.28 (t, J = 7.3 Hz, 1H), 4.79 (s, 2H), 4.69 (s, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>ClN<sub>5</sub>O<sup>+</sup> 342.1116, found 342.1126.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-3-chlorophenyl)methanol (28). White solid (6.8 mg, 78%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.42 – 7.30 (m, 3H), 7.26 – 7.09 (m, 5H), 4.53 (s, 2H), 4.49 (s, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>ClN<sub>5</sub>O<sup>+</sup> 342.1116, found 342.1123.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-6-methoxyphenyl)methanol (29). White solid (13 mg, 84%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.48 (t, *J* = 8.1 Hz, 1H), 7.40 (d, *J* = 7.2 Hz, 1H), 7.37 – 7.31 (m, 4H), 7.29 (dd, *J* = 7.8, 3.5 Hz, 2H), 4.82 (s, 2H), 4.69 (s, 2H), 3.91 (s, 3H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 338.1612, found 338.1618.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-4-methoxyphenyl)methanol (31). White solid (28 mg, 86%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.47 (dd, J = 8.6, 5.9 Hz, 1H), 7.44 (d, J = 2.8 Hz, 1H), 7.40 (d, J = 7.2 Hz, 1H), 7.35 (t, J = 7.6 Hz, 3H), 7.31 – 7.24 (m, 1H), 7.17 (dd, J = 8.5, 2.7 Hz, 1H), 4.72 (d, J = 2.8 Hz, 2H), 4.69 (d, J = 2.9 Hz, 2H), 3.86 (s, 3H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>

338.1612, found 338.1614.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-3-methoxyphenyl)methanol (32). White solid (16 mg, 48%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.54 (td, *J* = 8.2, 3.0 Hz, 1H), 7.42 – 7.32 (m, 4H), 7.29 (tt, *J* = 8.5, 4.8 Hz, 1H), 7.13 (dd, *J* = 7.9, 5.6 Hz, 2H), 4.68 (s, 2H), 4.68 (s, 2H), 3.88 (d, *J* = 1.6 Hz, 3H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 338.1612, found 338.1625.

**General Procedures for Preparation of Compounds 37-38.** Intermediate **36** was prepared according to previously published procedures<sup>60</sup>.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-5-ethoxyphenyl)methanol (37). То а dried microwave tube was added, intermediate 12 (23.6 mg, 0.1 mmol), intermediate 36 (39.2 mg, 0.2 mmol), tetrakis(triphenylphosphine)palladium (0) (5.8 mg, 5 mol %), and potassium carbonate (27.6 mg, 0.2 mmol %), dioxane (0.8 mL) and water (0.2 mL). The mixture was heated to 120 °C for 20 min under microwave. The resulting mixture was filtered through Celite with ethyl acetate as eluent solvent. The filter was washed with water and extracted with ethyl acetate. The combined organic layers were washed brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated *in vacuo*. The resulting residue was dissolved in 5 mL of THF. After the mixture was cooled to 0 °C, sodium borohydride (11 mg, 0.3 mmol) was added slowly. The reaction was warmed to room temperature and stirred for 10 min, before methanol was added slowly to quench the reaction. The mixture was washed with water and extracted with ethyl acetate. Combined organic layers were washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting residue was dissolved in 1.5 mL of methanol and purified by preparative HPLC to yield 37 as white solid (3.7 mg, 23%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.68 (d, J = 7.9 Hz, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.35 – 7.30 (m, 3H), 6.29 (s, 1H), 4.10 (s, 2H), 3.65 (s, 2H), 2.65 -2.51 (q, J = 7.2 Hz, 2H), 1.49 (t, J = 7.2 Hz, 3H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 352.1768, found 352.1762.

(2-(4-Amino-6-(benzylamino)-1,3,5-triazin-2-yl)-5-isopropoxyphenyl)methanol (38). White solid

(32 mg, 88%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.86 (d, *J* = 8.7 Hz, 1H), 7.39 (d, *J* = 7.3 Hz, 1H), 7.37 – 7.30 (m, 3H), 7.27 (t, *J* = 7.3 Hz, 1H), 7.14 (d, *J* = 2.6 Hz, 1H), 7.00 (dd, *J* = 8.8, 2.7 Hz, 1H), 4.81 (s, 2H), 4.78 – 4.72 (m, 1H), 4.68 (s, 2H), 1.35 (d, *J* = 6.0 Hz, 6H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 366.1925, found 366.1934.

## General Procedures for Preparation of Compounds 41-54, 56-60 and 64-81.

Intermediate 40 was prepared from intermediates 3, 11 and commercially available amines (intermediate **39**) according to the previously reported procedures.<sup>44</sup> Compounds **41-54**, **56-60** and **64**-66 were prepared following the general procedure for preparing compound 13 from intermediate 40 and (2-(hydroxymethyl)phenyl)boronic acid. Compounds 67-81 were prepared following the general procedure for preparing compound from intermediate and substituted (2 -(hydroxymethyl)phenyl)boronic acids.

(2-(4-Amino-6-((2-fluorobenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (41). White solid (27 mg, 82%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.82 (d, J = 7.7 Hz, 1H), 7.65 – 7.54 (m, 2H), 7.47 (dt, J = 26.2, 7.6 Hz, 2H), 7.33 – 7.25 (m, 1H), 7.13 (t, J = 7.7 Hz, 1H), 7.07 (t, J = 9.3 Hz, 1H), 4.79 (d, J = 3.9 Hz, 2H), 4.74 (s, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>FN<sub>5</sub>O<sup>+</sup> 326.1412, found 326.1443.

(2-(4-Amino-6-((3-fluorobenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (42). White solid (27 mg, 83%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.82 (d, *J* = 7.8 Hz, 1H), 7.65 – 7.56 (m, 2H), 7.49 (t, *J* = 7.9 Hz, 1H), 7.32 (td, *J* = 8.0, 5.7 Hz, 1H), 7.21 – 7.10 (m, 2H), 6.98 (td, *J* = 8.5, 2.6 Hz, 1H), 4.81 (s, 2H), 4.68 (s, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>FN<sub>5</sub>O<sup>+</sup> 326.1412, found 326.1435.

(2-(4-Amino-6-((4-fluorobenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (43). White solid (26 mg, 80%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.81 (dt, J = 7.9, 4.7 Hz, 1H), 7.72 – 7.53 (m, 3H), 7.49 (dd, J = 7.9, 4.8 Hz, 1H), 7.39 (dt, J = 9.7, 5.0 Hz, 1H), 7.03 (tt, J = 8.7, 4.5 Hz, 2H), 4.80 (t, J = 4.9 Hz, 2H), 4.64 (d, J = 4.9 Hz, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>FN<sub>5</sub>O<sup>+</sup> 326.1412, found 326.1438.

(2-(4-Amino-6-((2-chlorobenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (44). White solid (32 mg, 94%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.84 (d, J = 7.7 Hz, 1H), 7.68 – 7.58 (m, 2H), 7.54 – 7.47 (m, 2H), 7.41 (dd, J = 7.2, 2.0 Hz, 1H), 7.29 (ddt, J = 9.4, 6.9, 4.0 Hz, 2H), 4.83 (s, 2H), 4.79 (s, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>ClN<sub>5</sub>O<sup>+</sup> 342.1116, found 342.1113.

(2-(4-Amino-6-((3-chlorobenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (45). White solid (26 mg, 78%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (d, *J* = 7.4 Hz, 1H), 7.70 – 7.57 (m, 2H), 7.51 (td, *J* = 7.5, 1.5 Hz, 1H), 7.43 (d, *J* = 2.1 Hz, 1H), 7.36 – 7.19 (m, 3H), 4.83 (s, 2H), 4.69 (s, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>ClN<sub>5</sub>O<sup>+</sup> 342.1116, found 342.1102.

(2-(4-Amino-6-((4-chlorobenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (46). White solid (18 mg, 52%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (dd, J = 7.9, 1.2 Hz, 1H), 7.67 – 7.58 (m, 2H), 7.51 (td, J = 7.5, 1.5 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 9.0 Hz, 2H), 4.82 (s, 2H), 4.67 (s, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>17</sub>ClN<sub>5</sub>O<sup>+</sup> 342.1116, found 342.1108.

(2-(4-Amino-6-((2-(trifluoromethyl)benzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (47). White solid (35 mg, 93%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.86 (d, *J* = 7.7 Hz, 1H), 7.72 (t, *J* = 6.7 Hz, 1H), 7.67 – 7.55 (m, 4H), 7.53 (td, *J* = 7.5, 1.5 Hz, 1H), 7.47 (td, *J* = 7.4, 2.2 Hz, 1H), 4.93 (s, 2H), 4.85 (s, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sup>+</sup> 376.1380, found 376.1388.

(2-(4-Amino-6-((3-(trifluoromethyl)benzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (48). White solid (35 mg, 94%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (d, *J* = 7.6 Hz, 1H), 7.73 – 7.46 (m, 7H), 4.83 (s, 2H), 4.78 (s, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sup>+</sup> 376.1380, found 376.1367.

(2-(4-Amino-6-((4-(trifluoromethyl)benzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (49). White solid (36 mg, 96%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (dd, *J* = 7.8, 1.3 Hz, 1H), 7.67 – 7.55 (m, 3H), -6.76 (m, 1H), 4.82 (s, 2H), 4.66 (s, 2H), 3.78 (s, 3H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sup>+</sup> 376.1380, found 376.1374.

(2-(4-Amino-6-((2-methylbenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (50). White solid (28 mg, 88%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.82 (d, J = 7.7 Hz, 1H), 7.64 – 7.54 (m, 2H), 7.54 – 7.44 (m, 1H), 7.35 – 7.22 (m, 1H), 7.19 – 7.12 (m, 3H), 4.80 (s, 2H), 4.68 (s, 2H), 2.35 (s, 3H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sup>+</sup> 322.1662, found 322.1654.

(2-(4-Amino-6-((3-methylbenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (51). White solid (29 mg, 92%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.81 (d, *J* = 7.7 Hz, 1H), 7.68 – 7.55 (m, 2H), 7.50 (td, *J* = 7.5, 1.6 Hz, 1H), 7.25 – 7.13 (m, 3H), 7.08 (d, *J* = 7.3 Hz, 1H), 4.81 (s, 2H), 4.65 (s, 2H), 2.31 (s, 3H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sup>+</sup> 322.1662, found 322.1657.

(2-(4-Amino-6-((4-methylbenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (52). White solid (22 mg, 69%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.81 (d, J = 7.7 Hz, 1H), 7.70 – 7.57 (m, 2H), 7.55 – 7.47 (m, 1H), 7.27 (d, J = 7.8 Hz, 2H), 7.15 (d, J = 7.7 Hz, 2H), 4.81 (s, 2H), 4.64 (s, 2H), 2.29 (s, 3H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sup>+</sup> 322.1662, found 322.1672.

(2-(4-Amino-6-((2-methoxybenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (53). White solid (27 mg, 79%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.80 (d, *J* = 7.8 Hz, 1H), 7.66 – 7.58 (m, 2H), 7.49 (t, *J* = 7.6 Hz, 1H), 7.38 – 7.18 (m, 2H), 7.04 – 6.74 (m, 2H), 4.80 (s, 2H), 4.67 (s, 2H), 3.85 (s, 3H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 338.1612, found 338.1623.

(2-(4-Amino-6-((3-methoxybenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (54). White solid (29 mg, 87%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (dd, *J* = 7.8, 1.3 Hz, 1H), 7.67 – 7.55 (m, 3H), -6.76 (m, 1H), 4.82 (s, 2H), 4.66 (s, 2H), 3.78 (s, 3H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 338.1612, found 338.1618.

(2-(4-Amino-6-((4-ethoxybenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (56). White solid (32 mg, 93%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.81 (t, *J* = 6.4 Hz, 1H), 7.69 – 7.55 (m, 2H), 7.55 – 7.46 (m, 1H), 7.31 (td, *J* = 7.8, 7.0, 3.6 Hz, 1H), 6.95 – 6.79 (m, 3H), 4.81 (s, 2H), 4.60 (s, 2H), 4.00 (q, *J* = 6.7 Hz, 2H), 1.36 (t, *J* = 6.7 Hz, 3H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 352.1768, found

352.1765.

(2-(4-Amino-6-((4-isopropoxybenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (57). White solid (3.2 mg, 52%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (dd, J = 7.8, 1.3 Hz, 1H), 7.70 – 7.55 (m, 2H), 7.51 (td, J = 7.6, 1.5 Hz, 1H), 7.36 – 7.16 (m, 1H), 6.98 – 6.73 (m, 3H), 4.81 (s, 2H), 4.61 (s, 2H), 4.60 – 4.53 (m, 1H), 1.29 (d, J = 6.0 Hz, 6H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 366.1925, found 366.1928.

(2-(4-Amino-6-((4-cyclopropoxybenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (58). White solid (30 mg, 84%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (d, *J* = 7.8 Hz, 1H), 7.62 (dt, *J* = 21.8, 7.4 Hz, 2H), 7.51 (t, *J* = 7.5 Hz, 1H), 7.33 (d, *J* = 8.2 Hz, 2H), 7.02 (d, *J* = 8.2 Hz, 2H), 4.81 (s, 2H), 4.62 (s, 2H), 3.80 - 3.71 (m, 1H), 0.77 (t, *J* = 6.3 Hz, 2H), 0.66 (t, *J* = 2.9 Hz, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 364.1768, found 364.1776.

(2-(4-Amino-6-((4-phenoxybenzyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (59). White solid (13.4 mg, 84%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.82 (dd, J = 7.8, 1.2 Hz, 1H), 7.65 – 7.56 (m, 3H), 7.56 – 7.46 (m, 2H), 7.40 (d, J = 8.6 Hz, 1H), 7.32 (dd, J = 8.6, 7.3 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 8.5 Hz, 3H), 4.81 (s, 2H), 4.65 (s, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 400.1768, found 400.1743.

(2-(4-Amino-6-(phenylamino)-1,3,5-triazin-2-yl)phenyl)methanol (60). White solid (28 mg, 96%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.88 (d, *J* = 7.6 Hz, 1H), 7.75 (d, *J* = 7.9 Hz, 2H), 7.64 (dt, *J* = 17.2, 7.7 Hz, 2H), 7.53 (t, *J* = 7.5 Hz, 1H), 7.39 (t, *J* = 7.9 Hz, 2H), 7.21 (t, *J* = 7.4 Hz, 1H), 4.87 (s, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>16</sub>H<sub>16</sub>N<sub>5</sub>O<sup>+</sup> 294.1349, found 294.1341.

(2-(4-Amino-6-((4-phenoxyphenethyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (64). White solid (32 mg, 77%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) δ 7.82 (dd, *J* = 7.7, 1.3 Hz, 1H), 7.67 – 7.57 (m, 3H), 7.51 (td, *J* = 7.6, 1.4 Hz, 1H), 7.35 – 7.19 (m, 4H), 7.08 (t, *J* = 7.3 Hz, 1H), 6.93 (dd, *J* = 8.6, 6.8 Hz, 3H), 4.79 (s, 2H), 3.73 (t, *J* = 7.3 Hz, 2H), 2.94 (t, *J* = 7.4 Hz, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for

 $C_{24}H_{24}N_5O_2^+$  414.1925, found 414.1945.

(2-(4-Amino-6-((3-(4-phenoxyphenyl)propyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (65). White solid (18 mg, 87%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.83 (d, *J* = 7.8 Hz, 1H), 7.70 – 7.56 (m, 3H), 7.51 (t, *J* = 7.3 Hz, 1H), 7.31 (t, *J* = 7.7 Hz, 1H), 7.21 (d, *J* = 8.2 Hz, 2H), 7.07 (t, *J* = 7.4 Hz, 1H), 6.97 – 6.78 (m, 4H), 4.81 (s, 2H), 3.52 (t, *J* = 7.0 Hz, 2H), 2.71 (t, *J* = 6.1Hz, 2H), 2.08 – 1.86 (m, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>26</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 428.2081, found 428.2076.

(2-(4-Amino-6-((4-(4-phenoxyphenyl)butyl)amino)-1,3,5-triazin-2-yl)phenyl)methanol (66). White solid (17 mg, 73%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.82 (d, *J* = 7.8 Hz, 1H), 7.63 (dt, *J* = 22.8, 7.7 Hz, 3H), 7.52 (t, *J* = 7.5 Hz, 1H), 7.30 (q, *J* = 6.2, 4.7 Hz, 1H), 7.19 (d, *J* = 8.2 Hz, 2H), 7.06 (t, *J* = 7.4 Hz, 1H), 6.91 (dd, *J* = 23.1, 8.2 Hz, 4H), 4.81 (s, 2H), 3.52 (t, *J* = 6.4 Hz, 2H), 2.66 (q, *J* = 6.4 Hz, 2H), 1.70 (dt, *J* = 7.9, 3.9 Hz, 4H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>28</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> 442.2238, found 442.2234.

(2-(4-Amino-6-((2-fluorobenzyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (67). White solid (33 mg, 96%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.54 (td, *J* = 8.0, 5.5 Hz, 1H), 7.45 (td, *J* = 7.6, 1.7 Hz, 1H), 7.38 (d, *J* = 7.8 Hz, 1H), 7.34 – 7.26 (m, 1H), 7.23 – 7.13 (m, 2H), 7.13 – 7.04 (m, 1H), 4.71 (s, 2H), 4.68 (s, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>5</sub>O<sup>+</sup> 344.1317, found 344.1321.

(2-(4-Amino-6-((4-fluorobenzyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (68). White solid (32 mg, 92%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.58 (td, *J* = 8.0, 5.5 Hz, 1H), 7.44 – 7.31 (m, 3H), 7.25 – 7.19 (m, 1H), 7.08 (t, *J* = 8.6 Hz, 2H), 4.72 (s, 2H), 4.65 (s, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>5</sub>O<sup>+</sup> 344.1317, found 344.1323.

(2-(4-Amino-6-((3-methylbenzyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (69). White solid (32 mg, 94%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.61 – 7.53 (m, 1H), 7.39 (d, *J* = 7.7 Hz, 1H), 7.26 – 7.15 (m, 4H), 7.14 – 7.05 (m, 1H), 4.73 (s, 2H), 4.64 (s, 2H), 2.34 (s, 3H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>19</sub>FN<sub>5</sub>O<sup>+</sup> 340.1568, found 340.1562.

(2-(4-Amino-6-((2-methoxybenzyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (70). White solid (32 mg, 91%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.62 – 7.54 (m, 1H), 7.42 – 7.37 (m, 1H), 7.33 (dd, J = 7.4, 2.2 Hz, 1H), 7.31 – 7.26 (m, 1H), 7.26 – 7.20 (m, 1H), 6.98 (dd, J = 8.4, 2.1 Hz, 1H), 6.96 – 6.88 (m, 1H), 4.73 (s, 2H), 4.66 (s, 2H), 3.86 (s, 3H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>19</sub>FN<sub>5</sub>O<sub>2</sub><sup>+</sup> 356.1517, found 356.1523.

(2-(4-Amino-6-((4-phenoxybenzyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (71). White solid (16 mg, 75%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)  $\delta$  7.59 (td, *J* = 8.1, 5.6 Hz, 1H), 7.43 – 7.37 (m, 3H), 7.36 – 7.30 (m, 2H), 7.27 – 7.21 (m, 1H), 7.13 – 7.07 (m, 1H), 6.99 – 6.95 (m, 4H), 4.73 (s, 2H), 4.65 (s, 2H); <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD)  $\delta$  163.70, 163.17, 162.58, 160.59, 158.72, 158.44, 144.72, 134.40, 133.79, 131.03, 130.77, 125.63, 124.64, 120.03, 120.01, 116.34, 116.17, 62.66, 45.33. HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>2</sub><sup>+</sup> 418.1674, found 418.1665.

(2-(4-Amino-6-(phenethylamino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (72). White solid (30 mg, 89%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.60 (td, J = 8.2, 5.5 Hz, 1H), 7.41 (t, J = 8.8 Hz, 1H), 7.35 – 7.14 (m, 6H), 4.73 (d, J = 2.9 Hz, 2H), 3.71 (t, 2H), 2.95 (t, J = 7.5 Hz, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>19</sub>FN<sub>5</sub>O<sup>+</sup> 340.1568, found 340.1577.

(2-(4-Amino-6-((3-phenylpropyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (73). White solid (25 mg, 71%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.60 (td, *J* = 8.1, 5.6 Hz, 1H), 7.40 (d, *J* = 7.8 Hz, 1H), 7.29 – 7.23 (m, 2H), 7.23 – 7.10 (m, 4H), 4.73 (s, 2H), 3.50 (t, *J* = 7.2 Hz, 2H), 2.71 (t, *J* = 7.2 Hz, 2H), 2.04 – 1.89 (m, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>21</sub>FN<sub>5</sub>O<sup>+</sup> 354.1725, found 354.1735.

(2-(4-Amino-6-((4-phenylbutyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (74). White solid (23 mg, 64%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.65 – 7.56 (m, 1H), 7.40 (t, *J* = 6.6 Hz, 1H), 7.24 (ddt, *J* = 8.9, 5.1, 2.6 Hz, 3H), 7.21 – 7.17 (m, 2H), 7.14 (tt, *J* = 7.2, 1.5 Hz, 1H), 4.74 (s, 2H), 3.50 (t, 2H), 2.67 (t, *J* = 7.0 Hz, 2H), 1.81 – 1.53 (m, 4H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>23</sub>FN<sub>5</sub>O<sup>+</sup> 368.1881, found 368.1883.

(2-(4-Amino-6-((4-phenoxyphenethyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol (75). White solid (19 mg, 88%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.75 – 7.49 (m, 4H), 7.41 (t, *J* = 8.4 Hz, 1H), 7.32 (ddd, *J* = 8.6, 6.0, 2.1 Hz, 1H), 7.29 – 7.18 (m, 2H), 7.07 (t, *J* = 7.4 Hz, 1H), 6.99 – 6.85 (m, 3H), 4.73 (s, 2H), 3.72 (t, *J* = 7.4 Hz, 2H), 2.94 (t, *J* = 7.3 Hz, 2H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>2</sub><sup>+</sup> 432.1830, found 432.1832.

(2-(4-Amino-6-((3-(4-phenoxyphenyl)propyl)amino)-1,3,5-triazin-2-yl)-3-fluorophenyl)methanol

(76). White solid (16 mg, 70%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.64 – 7.46 (m, 1H), 7.39 (d, *J* = 7.4 Hz, 1H), 7.31 (ddd, *J* = 8.7, 7.4, 1.5 Hz, 2H), 7.26 – 7.13 (m, 4H), 7.07 (t, *J* = 7.4 Hz, 1H), 7.01 – 6.77 (m, 3H), 4.68 (s, 2H), 3.48 (t, *J* = 7.1 Hz, 2H), 2.70 (t, *J* = 7.7 Hz, 2H), 2.06 – 1.83 (m, 2H). HRMS *m/z* [M+H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>25</sub>FN<sub>5</sub>O<sub>2</sub><sup>+</sup> 446.1987, found 446.1978.

(2-(4-Amino-6-(phenethylamino)-1,3,5-triazin-2-yl)-4-chlorophenyl)methanol (77). White solid (15 mg, 43%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.84 (d, J = 2.2 Hz, 1H), 7.70 – 7.52 (m, 3H), 7.36 – 7.08 (m, 4H), 4.77 (s, 2H), 3.72 (t, J = 7.5 Hz, 2H), 2.95 (t, J = 7.6 Hz, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>18</sub>H<sub>19</sub>ClN<sub>5</sub>O<sup>+</sup> 356.1273, found 356.1278.

(2-(4-Amino-6-((3-phenylpropyl)amino)-1,3,5-triazin-2-yl)-4-chlorophenyl)methanol (78). White solid (7 mg, 19%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.86 (t, J = 1.7 Hz, 1H), 7.68 – 7.54 (m, 3H), 7.35 – 7.05 (m, 4H), 4.77 (s, 2H), 3.50 (t, J = 7.0 Hz, 2H), 2.71 (t, J = 7.7 Hz, 2H), 2.06 – 1.86 (m, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>19</sub>H<sub>21</sub>ClN<sub>5</sub>O<sup>+</sup> 370.1429, found 370.1423.

(2-(4-Amino-6-((4-phenylbutyl)amino)-1,3,5-triazin-2-yl)-4-chlorophenyl)methanol (79). White solid (12 mg, 32%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.86 (t, *J* = 3.4 Hz, 1H), 7.69 – 7.52 (m, 3H), 7.33 – 7.00 (m, 4H), 4.76 (s, 2H), 3.58 – 3.44 (m, 2H), 2.67 (q, *J* = 7.5, 6.9 Hz, 2H), 1.70 (tdd, *J* = 9.8, 5.3, 2.7 Hz, 4H). HRMS *m*/*z* [M+H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>23</sub>ClN<sub>5</sub>O<sup>+</sup> 384.1586, found 384.1589.

(2-(4-Amino-6-((4-phenoxybenzyl)amino)-1,3,5-triazin-2-yl)-4-chlorophenyl)methanol (80). White solid (8 mg, 18%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) δ 7.91 – 7.87 (m, 1H), 7.63 – 7.53 (m, 2H), 7.39 (d, J

= 8.5 Hz, 2H), 7.35 – 7.30 (m, 2H), 7.10 (t, J = 7.6 Hz, 1H), 6.99 – 6.93 (m, 4H), 4.75 (s, 2H), 4.64 (s, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>21</sub>ClN<sub>5</sub>O<sub>2</sub><sup>+</sup> 434.1387, found 434.1376.

(2-(4-Amino-6-((4-phenoxyphenethyl)amino)-1,3,5-triazin-2-yl)-4-chlorophenyl)methanol (81). White solid (16 mg, 36%). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD)  $\delta$  7.86 (d, J = 2.2 Hz, 1H), 7.57 (dt, J = 10.6, 8.4 Hz, 2H), 7.38 – 7.19 (m, 4H), 7.13 – 7.04 (m, 1H), 7.01 – 6.81 (m, 4H), 4.74 (s, 2H), 3.78 – 3.65 (m, 2H), 2.93 (t, J = 7.5 Hz, 2H). HRMS m/z [M+H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>23</sub>ClN<sub>5</sub>O<sub>2</sub><sup>+</sup> 448.1535, found 448.1537.

**Calcium release assays.** Calcium release assays for  $G_q$ -GPCRs were performed according to published protocol<sup>61</sup> with minor modifications. In brief, HEK293 cells stably expressing 5-HT<sub>2B</sub> receptors<sup>62</sup> were plated in 384-well black clear bottom plates (coated with poly-L-Lys) at a density of 10,000 cells/well in DMEM supplemented with 1% dFBS overnight (16 – 20 h). The cells were loaded with Fluo-4 Direct Calcium dye (20 µL/well) for 1 h at 37 °C in FLIPR buffer (1x HBSS, 20 mM HEPES, 2.5 mM probenecid, pH 7.40, room temperature). Drug working dilutions (3x of final) were prepared in the FLIPR buffer supplemented with 1 mg/mL BSA and 0.1 mg/mL ascorbic acid. The FLIPR<sup>TETRA</sup> was programmed to transfer 10 µL/well of drug solution and fluorescence was recorded for a total of 2 minutes with 1 read per second and 10 seconds before drug addition. The maximum fluorescence intensity (fold of basal) within the first minute of drug addition was exported and analyzed in Prism.

**GloSensor cAMP assays**. Proton-mediated GPR68  $G_s$  activation was determined by measuring cAMP production using GloSensor cAMP assays as reported previously<sup>44</sup> with modifications as detailed below. Calcium- and magnesium-free Hank's Balanced Salt Solution (1x HBSS) was used to as the base for all pH buffers. Different zwitterionic organic buffer agents were used for different pH ranges, 1x HBSS with 20 mM 2-(*N*-morpholino)ethanesulfonic acid (MES) for pH 5.60 – 6.70, 1x HBSS with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) for pH 6.80 – 8.20, and 1x HBSS with 20 mM (tris(hydroxymethyl)methylamino)propanesulfonic acid (TAPS) for pH 8.30 – 8.60. The

pH was adjusted with KOH and fresh buffers were made in the morning to use within 24 h. The phosphodiesterase (PDE) inhibitor Ro 20-1724 (10 µM) was included in assay buffer to eliminate potential effect of PDE inhibition. BSA (1mg/mL) was added to buffer for samples with solubility issues. Addition of BSA does not affect GloSensor cAMP assays and is routinely applied in cell-based GPCR functional assays.<sup>63,64</sup> Briefly, HEK293T cells were co-transfected with a modified Polyethylenimine (PEI) transfection method.<sup>65</sup> For a 10-cm dish of HEK293T cells with 12 mL growth medium, 4 ug receptor DNA and 4 ug GloSensor DNA were mixed in 0.4 mL of Opti-MEM medium followed by addition of 40 µL PEI reagent (increase proportionally when larger dishes are used). The mixture was incubated for 20 min at room temperature and then added to cells for incubation overnight (16-20 h). Transfected cells were plated in poly-L-Lys coated 384-well white clear bottom plates using DMEM + 1% dFBS for a minimum of 6 h (up to 24 h) before being used for assays. After culture medium was removed, cells were incubated with 20 µL/well of 3.5 mM luciferin prepared in assay buffer (1x HBSS, 20 mM TAPS, pH 8.40) for 1 h at 37 °C. Ligand stock was made in DMSO at 10 mM and diluted with pH buffers to desired concentrations. To stimulate cells with premixed drug solutions at desired pH conditions, luciferin-loading solution was removed before addition of drug solution (25  $\mu$ L/well). Luminescence was counted at 20 – 30 min after drug application and data were analyzed in the GraphPad Prism.

**GPCRome off-target agonist assays.** Off-target agonist activity was carried out according to previously published procedure using the PRESTO-Tango assay platform<sup>47</sup> with modifications as outlined below. The assay was designed and modified such that 40 receptors were tested in each 384-well plate, each in quadruplicate wells for basal (with medium vehicle) and in quadruplicate for sample. Each plate also contained 16-wells of dopamine D<sub>2</sub> receptors stimulated with 100 nM quinpirole as assay controls and 16-wells of D<sub>2</sub> with vehicle alone as D<sub>2</sub> basal activity. In addition, there were 2 columns of wells (32-wells) of untransfected cells as negative controls. The whole procedure takes 3 days from plating cells to reading plates. In brief, HTLA cells were plated in poly-L-Lys coated 384-

#### Journal of Medicinal Chemistry

well white clear bottom plates in DMEM supplemented with 2% dFBS (10,000 cells per 40 µl per well) overnight, transfected with receptor Tango constructs (15 ng/well) overnight using an in-plate PEI transfection method,<sup>65</sup> in which receptor DNA was resuspended in OptiMEM and hybridized with PEI reagent prior to dilution and distribution to 384-well plates and subsequent addition to cells. After overnight incubation, cells received drugs without replacement of the medium and were incubated overnight. Drug solutions and medium were removed and Bright-Glo reagent (20 µL/well) were added. Luminescence was counted on a luminescence reader after 20 min incubation at room temperature. Results were presented in the form of fold of basal for each receptor and analyzed in the Prism.

For Tango Arresting Recruitment concentration responses with individual GPCRs, HTLA cells were transfected with receptor DNA overnight in DMEM with 10% FBS and plated into poly-L-Lys coated 384-well plates as above using DMEM supplemented with 1% dFBS. Drugs were added 6 h later and incubated for overnight (16 – 20 h). Medium and drug solutions were removed and Bright-Glo reagent (20  $\mu$ L/well) was added. Luminescence was counted and results were analyzed in Prism.

**Radioligand binding assays.** Ligand binding profiling was performed by the NIMH PDSP. The NIMH PDSP is directed by Bryan L Roth, MD, Ph.D. at the University of North Carolina at Chapel Hill, North Carolina, and Program Officer Jamie Driscoll at NIMH, Bethesda, MD. Detail binding assay procedures and protocols are available online here at: https://pdspdb.unc.edu/pdspWeb/?site=assays.

**Data analysis**. Proton-mediated GPR68 G<sub>s</sub> activity, as measured as relative luminescence unit (RLU), in the absence and presence of increasing concentrations of ligands was fitted to the standard allosteric operational model to obtain allosteric parameters, affinity cooperativity  $\alpha$  and efficacy cooperativity  $\beta$ , and allosteric ligand binding affinity K<sub>B</sub>.<sup>26–28</sup> Briefly, affinity cooperativity  $\alpha$  defines the reciprocal effect between allosteric modulator and orthosteric agonist (protons in this case) with  $\alpha > 1$  for increasing affinity and  $0 < \alpha < 1$  for reducing affinity. Efficacy cooperativity  $\beta$  defines the effect of allosteric modulator on the efficacy of the orthosteric agonist (protons in this case) with  $\beta > 1$  for

increasing proton efficacy and  $0 < \beta < 1$  for reducing proton efficacy. The K<sub>B</sub> defines the equilibrium binding affinity of test allosteric ligands in the absence of orthosteric agonist (H<sup>+</sup>). Since orthosteric agonist protons always exist in the receptor compartment, K<sub>B</sub> in this case has no physical meaning. We applied the comprehensive index Log( $\alpha\beta/K_B$ ) to quantify the overall allosteric activity of test allosteric ligand and the difference from that of reference ligand,  $\Delta Log(\alpha\beta/K_B)$ , to represent the net change of allosteric activity.<sup>31</sup> For summary, results were normalized to the percentages, pooled together, and analyzed in the Prism. Normalization was performed using the built-in normalization function in the Prism, where proton basal activity in the absence of test allosteric ligand was set as 0% and the maximum proton activity in the absence of test allosteric ligand was set as 100%. In functional antagonist assays, functional affinity (K<sub>i</sub>) values were calculated from IC<sub>50</sub> values using the Cheng-Prusoff equation K<sub>i</sub> = IC<sub>50</sub>/(1+L/EC<sub>50</sub>),<sup>66</sup> where IC<sub>50</sub> is the antagonist concentration when 50% inhibition is achieved against reference agonist at concentration [L], EC<sub>50</sub> is the potency of the reference agonist.

**Mouse pharmacokinetic study.** A standard PK study was performed. Compound **71** was dissolved in 5% NMP, 5% Solutol HS-15 and 90% Normal Saline. Nine male Swiss Albino mice were treated with compound **71** intraperitoneally at the 25 mg/kg dose. Plasma and brain samples were collected at 0.5, 1.0 and 2.0 h. Compound concentrations in plasma and brain at each time point are average values from 3 test mice. Error bars represent ± SEM.

## ASSOCIATED CONTENT

## **Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website.

<sup>1</sup>H NMR spectra of compounds **46**, **71**, **77**, and **78**; <sup>13</sup>C NMR spectra of compound **71**; Proton concentration response curves at human GPR68 in the absence and presence of increasing concentrations of test compounds; Proton concentration response curves of compounds **20**, **46**, **77**, and ACS Paragon Plus Environment

#### Journal of Medicinal Chemistry

**78** at GPR4 and GPR65; Heat map showing off-target binding activities of selected lead compounds at 48 common GPCRs, ion channels and transporters; Functional activities of compounds with binding affinity values lower than 300 nM (pK<sub>i</sub> > 6.50); Off-target agonist activity at human GPCRome; Functional characterization of the compounds identified from the GPCRome screening; Proton concentration response curves of compound **1**, **46**, **63**, **71**, **77**, and **78** at mouse GPR68; Effects of inactive analogs on the GPR68 PAM **71**; Allosteric modulation of GPR68 proton activity: implications for pH-dependent agonism and inverse agonism (PDF).

Molecular formula strings for all compounds (CSV)

## **AUTHOR INFORMATION**

**Corresponding Authors** 

\*E-mail: <u>xphuang@unc.edu</u> (X.-P.H.).

\*E-mail: jing.liu@mssm.edu (J.L.).

\*E-mail: jian.jin@mssm.edu (J.J.).

<sup>#</sup>These authors contributed equally to this work.

## ORCID

Jian Jin: 0000-0002-2387-3862

## Notes

The authors declare no competing financial interests.

# ACKNOWLEDGEMENTS

The research described here was in part supported by the grants R56MH111789 (to X.-P.H. and T.K.) and U24DK116195 (to J.J.) from the U.S. National Institutes of Health, and by the PDSP contract

HHSN-271-2013-00017-C from the U.S. National Institute of Mental Health. M.L.M. acknowledges the support by the NIGMS-funded Integrated Pharmacological Sciences Training Program T32GM062754 and the MSTP training grants at the Icahn School of Mount Sinai (NIH T32GM007280).

#### **ABBREVIATIONS USED**

GPCR, G protein-coupled receptor; SAR, structure-activity relationship;  $G_s$ , stimulatory G protein; cAMP, cyclic adenosine monophosphate; PAM, positive allosteric modulator; MT<sub>1</sub>, melatonin receptor 1; MT<sub>2</sub>, melatonin receptor 2; ACKR3, atypical chemokine receptor 3; 5-HT<sub>2B</sub>, 5-hydroxytryptamine receptor 2B; mGLuR5, metabotropic glutamate receptor 5; D<sub>2</sub>, dopamine D<sub>2</sub> receptor; TFA, trifluoroacetic acid; Na<sub>2</sub>SO<sub>4</sub>, sodium sulfate; Dioxane, 1,4-dioxane; THF, tetrahydrofuran; K<sub>2</sub>CO<sub>3</sub>, potassium carbonate; Pd(PPh<sub>3</sub>)<sub>4</sub>, tetrakis(triphenylphosphine)palladium (0); MgSO<sub>4</sub>, magnesium sulfate; NaBH<sub>4</sub>, sodium borohydride; "BuLi, *n*-butyllithium solution; B(OMe)<sub>3</sub>, trimethyl borate.

## REFERENCES

- Xu, Y.; Casey, G. Identification of Human OGR1, a Novel G Protein-Coupled Receptor That Maps to Chromosome 14. *Genomics* 1996, *35*, 397–402.
- (2) Ludwig, M.-G.; Vanek, M.; Guerini, D.; Gasser, J. A.; Jones, C. E.; Junker, U.; Hofstetter, H.;
   Wolf, R. M.; Seuwen, K. Proton-Sensing G-Protein-Coupled Receptors. *Nature* 2003, 425, 93–98.
- Regard, J. B.; Sato, I. T.; Coughlin, S. R. Anatomical Profiling of G Protein-Coupled Receptor Expression. *Cell* 2008, *135*, 561–571.
- (4) Alexander, S. P.; Christopoulos, A.; Davenport, A. P.; Kelly, E.; Marrion, N. V.; Peters, J. A.;
   Faccenda, E.; Harding, S. D.; Pawson, A. J.; Sharman, J. L.; Southan, C.; Davies, J. A.; CGTP

Collaborators. The Concise Guide to Pharmacology 2017/18: G Protein-Coupled Receptors. *Br. J. Pharmacol.* **2017**, *174 Suppl 1*, S17–S129.

- (5) Mogi, C.; Tomura, H.; Tobo, M.; Wang, J.-Q.; Damirin, A.; Kon, J.; Komachi, M.; Hashimoto, K.; Sato, K.; Okajima, F. Sphingosylphosphorylcholine Antagonizes Proton-Sensing Ovarian Cancer G-Protein-Coupled Receptor 1 (OGR1)-Mediated Inositol Phosphate Production and cAMP Accumulation. *J Pharmacol Sci* 2005, *99*, 160–167.
- (6) Singh, L. S.; Berk, M.; Oates, R.; Zhao, Z.; Tan, H.; Jiang, Y.; Zhou, A.; Kirmani, K.; Steinmetz, R.; Lindner, D.; Xu, Y. Ovarian Cancer G Protein-Coupled Receptor 1, a New Metastasis Suppressor Gene in Prostate Cancer. J. Natl. Cancer Inst. 2007, 99, 1313–1327.
- Li, J.; Guo, B.; Wang, J.; Cheng, X.; Xu, Y.; Sang, J. Ovarian Cancer G Protein Coupled Receptor 1 Suppresses Cell Migration of MCF7 Breast Cancer Cells via a Gα12/13-Rho-Rac1 Pathway. J. Mol. Signal. 2013, 8, 6.
- (8) Damaghi, M.; Wojtkowiak, J. W.; Gillies, R. J. pH Sensing and Regulation in Cancer. *Front. Physiol.* 2013, *4*, 370.
- Li, H.; Wang, D.; Singh, L. S.; Berk, M.; Tan, H.; Zhao, Z.; Steinmetz, R.; Kirmani, K.; Wei, G.;
   Xu, Y. Abnormalities in Osteoclastogenesis and Decreased Tumorigenesis in Mice Deficient for
   Ovarian Cancer G Protein-Coupled Receptor 1. *PLoS One* 2009, *4*, e5705.
  - (10) Ren, J.; Zhang, L. Effects of Ovarian Cancer G Protein Coupled Receptor 1 on the Proliferation,
     Migration, and Adhesion of Human Ovarian Cancer Cells. *Chin. Med. J.* 2011, *124*, 1327–1332.
  - Wiley, S. Z.; Sriram, K.; Liang, W.; Chang, S. E.; French, R.; McCann, T.; Sicklick, J.;
     Nishihara, H.; Lowy, A. M.; Insel, P. A. GPR68, a Proton-Sensing GPCR, Mediates Interaction of Cancer-Associated Fibroblasts and Cancer Cells. *FASEB J.* 2018, *32*, 1170–1183.

- (12) Okajima, F. Regulation of Inflammation by Extracellular Acidification and Proton-Sensing GPCRs. *Cell Signal.* 2013, 25, 2263–2271.
- (13) Chen, Y.-J.; Huang, C.-W.; Lin, C.-S.; Chang, W.-H.; Sun, W.-H. Expression and Function of Proton-Sensing G-Protein-Coupled Receptors in Inflammatory Pain. *Mol. Pain* 2009, *5*, 39.
- (14) de Vallière, C.; Wang, Y.; Eloranta, J. J.; Vidal, S.; Clay, I.; Spalinger, M. R.; Tcymbarevich, I.; Terhalle, A.; Ludwig, M.-G.; Suply, T.; Fried, M.; Kullak-Ublick, G. A.; Frey-Wagner, I.; Scharl, M.; Seuwen, K.; Wagner, C. A.; Rogler, G. G Protein-Coupled pH-Sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation. *Inflamm. Bowel Dis.* 2015, *21*, 1269–1281.
- (15) Yang, M.; Mailhot, G.; Birnbaum, M. J.; MacKay, C. A.; Mason-Savas, A.; Odgren, P. R. Expression of and Role for Ovarian Cancer G-Protein-Coupled Receptor 1 (OGR1) During Osteoclastogenesis. J. Biol. Chem. 2006, 281, 23598–23605.
- (16) Pereverzev, A.; Komarova, S. V.; Korcok, J.; Armstrong, S.; Tremblay, G. B.; Dixon, S. J.;
   Sims, S. M. Extracellular Acidification Enhances Osteoclast Survival through an NFAT-Independent, Protein Kinase C-Dependent Pathway. *Bone* 2008, *42*, 150–161.
- (17) Aoki, H.; Mogi, C.; Hisada, T.; Nakakura, T.; Kamide, Y.; Ichimonji, I.; Tomura, H.; Tobo, M.;
  Sato, K.; Tsurumaki, H.; Dobashi, K.; Mori, T.; Harada, A.; Yamada, M.; Mori, M.; Ishizuka, T.;
  Okajima, F. Proton-Sensing Ovarian Cancer G Protein-Coupled Receptor 1 on Dendritic Cells is
  Required for Airway Responses in a Murine Asthma Model. *PLoS One* 2013, *8*, e79985.
- (18) Nakakura, T.; Mogi, C.; Tobo, M.; Tomura, H.; Sato, K.; Kobayashi, M.; Ohnishi, H.; Tanaka, S.; Wayama, M.; Sugiyama, T.; Kitamura, T.; Harada, A.; Okajima, F. Deficiency of Proton-Sensing Ovarian Cancer G Protein-Coupled Receptor 1 Attenuates Glucose-Stimulated Insulin Secretion. *Endocrinology* **2012**, *153*, 4171–4180.

- Mohebbi, N.; Benabbas, C.; Vidal, S.; Daryadel, A.; Bourgeois, S.; Velic, A.; Ludwig, M.-G.;
   Seuwen, K.; Wagner, C. A. The Proton-Activated G Protein Coupled Receptor OGR1 Acutely
   Regulates the Activity of Epithelial Proton Transport Proteins. *Cell Physiol. Biochem.* 2012, 29, 313–324.
- (20) de Vallière, C.; Vidal, S.; Clay, I.; Jurisic, G.; Tcymbarevich, I.; Lang, S.; Ludwig, M.-G.; Okoniewski, M.; Eloranta, J. J.; Kullak-Ublick, G. A.; Wagner, C. A.; Rogler, G.; Seuwen, K. The pH-Sensing Receptor OGR1 Improves Barrier Function of Epithelial Cells and Inhibits Migration in an Acidic Environment. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2015, *309*, G475–90.
- (21) Xu, J.; Mathur, J.; Vessières, E.; Hammack, S.; Nonomura, K.; Favre, J.; Grimaud, L.; Petrus, M.; Francisco, A.; Li, J.; Lee, V.; Xiang, F.-L.; Mainquist, J. K.; Cahalan, S. M.; Orth, A. P.; Walker, J. R.; Ma, S.; Lukacs, V.; Bordone, L.; Bandell, M.; Laffitte, B.; Xu, Y.; Chien, S.; Henrion, D.; Patapoutian, A. GPR68 Senses Flow and Is Essential for Vascular Physiology. *Cell* 2018, *173*, 762–775.e16.
  - (22) Illuminating the Druggable Genome | NIH Common Fund https://www.commonfund.nih.gov/idg/ (accessed May 7, 2019).
  - Wiley, S. Z.; Sriram, K.; Salmerón, C.; Insel, P. A. GPR68: An Emerging Drug Target in Cancer.
     *Int. J. Mol. Sci.* 2019, 20, 559.
  - (24) Lu, S.; Zhang, J. Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions. *J. Med. Chem.* 2019, *62*, 24–45.
  - (25) Coughlin, Q.; Hopper, A. T.; Blanco, M.-J.; Tirunagaru, V.; Robichaud, A. J.; Doller, D. Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain

Diseases. *J. Med. Chem.* [Online early access]. DOI: 10.1021/acs.jmedchem.8b01651. Published Online: February 5, 2019.

- (26) Kenakin, T. New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism.
   *Nat. Rev. Drug Discov.* 2005, *4*, 919–927.
- (27) Ehlert, F. J. Analysis of Allosterism in Functional Assays. J. Pharmacol. Exp. Ther. 2005, 315, 740–754.
- (28) Price, M. R.; Baillie, G. L.; Thomas, A.; Stevenson, L. A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos, A.; Pertwee, R. G.; Ross, R. A. Allosteric Modulation of the Cannabinoid CB1 Receptor. *Mol. Pharmacol.* 2005, *68*, 1484–1495.
- Mistry, S. N.; Valant, C.; Sexton, P. M.; Capuano, B.; Christopoulos, A.; Scammells, P. J. Synthesis and Pharmacological Profiling of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric Modulators of the M1 Muscarinic Receptor. *J. Med. Chem.* 2013, *56*, 5151–5172.
- Bradley, S. J.; Bourgognon, J.-M.; Sanger, H. E.; Verity, N.; Mogg, A. J.; White, D. J.; Butcher, A. J.; Moreno, J. A.; Molloy, C.; Macedo-Hatch, T.; Edwards, J. M.; Wess, J.; Pawlak, R.; Read, D. J.; Sexton, P. M.; Broad, L. M.; Steinert, J. R.; Mallucci, G. R.; Christopoulos, A.; Felder, C. C.; Tobin, A. B. M1 Muscarinic Allosteric Modulators Slow Prion Neurodegeneration and Restore Memory Loss. *J. Clin. Invest.* 2017, *127*, 487–499.
  - (31) Kenakin, T. A Scale of Agonism and Allosteric Modulation for Assessment of Selectivity, Bias, and Receptor Mutation. *Mol. Pharmacol.* **2017**, *92*, 414–424.
  - (32) Mistry, S. N.; Jörg, M.; Lim, H.; Vinh, N. B.; Sexton, P. M.; Capuano, B.; Christopoulos, A.;Lane, J. R.; Scammells, P. J. 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive

Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor. J. Med. Chem. 2016, 59, 388–409.

- (33) Russell, J. L.; Goetsch, S. C.; Aguilar, H. R.; Coe, H.; Luo, X.; Liu, N.; van Rooij, E.; Frantz, D. E.; Schneider, J. W. Regulated Expression of pH Sensing G Protein-Coupled Receptor-68 Identified through Chemical Biology Defines a New Drug Target for Ischemic Heart Disease. *ACS Chem. Biol.* 2012, *7*, 1077–1083.
  - (34) Mogi, C.; Nakakura, T.; Okajima, F. Role of Extracellular Proton-Sensing OGR1 in Regulation of Insulin Secretion and Pancreatic toCell Functions. *Endocr. J.* 2014, *61*, 101r. J.
  - (35) Abe-Ohya, R.; Ishikawa, T.; Shiozawa, H.; Suda, K.; Nara, F. Identification of Metals from Osteoblastic ST-2 Cell Supernatants as Novel OGR1 Agonists. *J. Recept. Signal Transduct. Res.* 2015, 35, 485–492.
  - (36) Negishi, J.; Omori, Y.; Shindo, M.; Takanashi, H.; Musha, S.; Nagayama, S.; Hirayama, J.; Nishina, H.; Nakakura, T.; Mogi, C.; Sato, K.; Okajima, F.; Mochimaru, Y.; Tomura, H. Manganese and Cobalt Activate Zebrafish Ovarian Cancer G-protein-Coupled Receptor 1 but Not GPR4. *J. Recept. Signal Transduct. Res.* 2017, *37*, 401–408.
- (37) Mochimaru, Y.; Negishi, J.; Murakami, S.; Musha, S.; Sato, K.; Okajima, F.; Tomura, H. Metals Differentially Activate Ovarian Cancer G Protein-Coupled Receptor 1 in Various Species. *Zool Sci.* 2018, 35, 109–114.
- (38) Yasuda, S.; Miyazaki, T.; Munechika, K.; Yamashita, M.; Ikeda, Y.; Kamizono, A. Isolation of Zn2+ as an Endogenous Agonist of GPR39 from Fetal Bovine Serum. J. Recept. Signal Transduct. Res. 2007, 27, 235–246.

(39)	Holst, B.; Egerod, K. L.; Schild, E.; Vickers, S. P.; Cheetham, S.; Gerlach, LO.; Storjohann, L.;
	Stidsen, C. E.; Jones, R.; Beck-Sickinger, A. G.; Schwartz, T. W. GPR39 Signaling Is Stimulated
	by Zinc Ions but Not by Obestatin. Endocrinology 2007, 148, 13–20.
(40)	Sato, S.; Huang, XP.; Kroeze, W. K.; Roth, B. L. Discovery and Characterization of Novel
	GPR39 Agonists Allosterically Modulated by Zinc. Mol. Pharmacol. 2016, 90, 726–737.
(41)	Ayton, S.; Lei, P.; Bush, A. I. Biometals and Their Therapeutic Implications in Alzheimer's
	Disease. Neurotherapeutics 2015, 12, 109–120.
(42)	Nordberg, M.; Nordberg, G. F. Trace Element Research-Historical and Future Aspects. J. Trace
	<i>Elem. Med. Biol.</i> <b>2016</b> , <i>38</i> , 46–52.
(43)	Prakash, A.; Dhaliwal, G. K.; Kumar, P.; Majeed, A. B. A. Brain Biometals and Alzheimer's
	Disease - Boon or Bane? Int. J. Neurosci. 2017, 127, 99–108.
(44)	Huang, XP.; Karpiak, J.; Kroeze, W. K.; Zhu, H.; Chen, X.; Moy, S. S.; Saddoris, K. A.;
	Nikolova, V. D.; Farrell, M. S.; Wang, S.; Mangano, T. J.; Deshpande, D. A.; Jiang, A.; Penn, R.
	B.; Jin, J.; Koller, B. H.; Kenakin, T.; Shoichet, B. K.; Roth, B. L. Allosteric Ligands for the
	Pharmacologically Dark Receptors GPR68 and GPR65. <i>Nature</i> 2015, 527, 477–483.
(45)	McAleer, J. P.; Fan, J.; Roar, B.; Primerano, D. A.; Denvir, J. Cytokine Regulation in Human
	CD4 T Cells by the Aryl Hydrocarbon Receptor and Gq-Coupled Receptors. Sci. Rep. 2018, 8,

- (46) Irwin, J. J.; Sterling, T.; Mysinger, M. M.; Bolstad, E. S.; Coleman, R. G. ZINC: a Free Tool to Discover Chemistry for Biology. J. Chem. Inf. Model. 2012, 52, 1757–1768.
- (47) Kroeze, W. K.; Sassano, M. F.; Huang, X.-P.; Lansu, K.; McCorvy, J. D.; Giguère, P. M.; Sciaky, N.; Roth, B. L. PRESTO-Tango as an Open-Source Resource for Interrogation of the Druggable Human GPCRome. *Nat. Struct. Mol. Biol.* 2015, *22*, 362–369.

10954.

- (48) Bachelerie, F.; Ben-Baruch, A.; Burkhardt, A. M.; Combadiere, C.; Farber, J. M.; Graham, G. J.; Horuk, R.; Sparre-Ulrich, A. H.; Locati, M.; Luster, A. D.; Mantovani, A.; Matsushima, K.; Murphy, P. M.; Nibbs, R.; Nomiyama, H.; Power, C. A.; Proudfoot, A. E. I.; Rosenkilde, M. M.; Rot, A.; Sozzani, S.; Thelen, M.; Yoshie, O.; Zlotnik, A. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. *Pharmacol. Rev.* 2014, *66*, 1–79.
- (49) Bachelerie, F.; Graham, G. J.; Locati, M.; Mantovani, A.; Murphy, P. M.; Nibbs, R.; Rot, A.;
  Sozzani, S.; Thelen, M. An Atypical Addition to the Chemokine Receptor Nomenclature: IUPHAR Review 15. *Br. J. Pharmacol.* 2015, *172*, 3945–3949.
- (50) Nickols, H. H.; Conn, P. J. Development of Allosteric Modulators of GPCRs for Treatment of CNS Disorders. *Neurobiol. Dis.* 2014, *61*, 55–71.
- (51) Burford, N. T.; Clark, M. J.; Wehrman, T. S.; Gerritz, S. W.; Banks, M.; O, M.; Oks, M.;Traynor, J. R.; Alt, A. Discovery of Positive Allosteric Modulators and Silent Allosteric Modulators of the μ-Opioid Receptor. *Proc. Natl. Acad. Sci. USA* 2013, *110*, 10830–10835.
- (52) Livingston, K. E.; Stanczyk, M. A.; Burford, N. T.; Alt, A.; Canals, M.; Traynor, J. R.
   Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors. *Mol. Pharmacol.* 2018, *93*, 157–167.
- (53) Haas, L. T.; Salazar, S. V.; Smith, L. M.; Zhao, H. R.; Cox, T. O.; Herber, C. S.; Degnan, A. P.; Balakrishnan, A.; Macor, J. E.; Albright, C. F.; Strittmatter, S. M. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling While Rescuing Alzheimer's Mouse Phenotypes. *Cell Rep.* 2017, *20*, 76–88.

- (54) Sharma, S.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Synthesis and SAR of a mGluR5 Allosteric Partial Antagonist Lead: Unexpected Modulation of Pharmacology with Slight Structural Modifications to a 5-(Phenylethynyl)pyrimidine Scaffold. *Bioorg. Med. Chem. Lett.* 2008, 18, 4098–4101.
- (55) Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. Molecular Switches" on mGluR Allosteric Ligands That Modulate Modes of Pharmacology. *Biochemistry* 2011, 50, 2403–2410.
- (56) Gregory, K. J.; Conn, P. J. Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation. *Mol. Pharmacol.* 2015, *88*, 188–202.
- (57) Sassano, M. F.; Doak, A. K.; Roth, B. L.; Shoichet, B. K. Colloidal Aggregation Causes Inhibition of G Protein-Coupled Receptors. J. Med. Chem. 2013, 56, 2406–2414.
- (58) Owen, S. C.; Doak, A. K.; Ganesh, A. N.; Nedyalkova, L.; McLaughlin, C. K.; Shoichet, B. K.; Shoichet, M. S. Colloidal Drug Formulations Can Explain "Bell-shaped" Concentration-Response Curves. ACS Chem. Biol. 2014, 9, 777–784.
- (59) Vijayaraghavan, S.; Mahajan, S. Docking, Synthesis and Antimalarial Activity of Novel 4-Anilinoquinoline Derivatives. *Bioorg. Med. Chem. Lett.* 2017, 27, 1693–1697.
- (60) Yu, X.; Lu, X. Cationic Palladium Complex Catalyzed Diastereo- and Enantioselective Tandem Annulation of 2-Formylarylboronic Acids with Allenoates. *Org. Lett.* 2009, *11*, 4366–4369.
- (61) Huang, X.-P.; Setola, V.; Yadav, P. N.; Allen, J. A.; Rogan, S. C.; Hanson, B. J.; Revankar, C.; Robers, M.; Doucette, C.; Roth, B. L. Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine(2B) Receptor Agonists: Implications for Drug Safety Assessment. *Mol. Pharmacol.* 2009, *76*, 710–722.

1	(62)	McCorvy, J. D.; Wacker, D.; Wang, S.; Agegnehu, B.; Liu, J.; Lansu, K.; Tribo, A. R.; Olsen, R.
2 3		H. J.; Che, T.; Jin, J.; Roth, B. L. Structural Determinants of 5-HT2B Receptor Activation and
4 5 6		Biased Agonism. Nat. Struct. Mol. Biol. 2018, 25, 787–796.
7 8 9	(63)	Stauch, B.; Johansson, L. C.; McCorvy, J. D.; Patel, N.; Han, G. W.; Huang, XP.; Gati, C.;
10 11		Batyuk, A.; Slocum, S. T.; Ishchenko, A.; Brehm, W.; White, T. A.; Michaelian, N.; Madsen, C.;
12 13		Zhu, L.; Grant, T. D.; Grandner, J. M.; Shiriaeva, A.; Olsen, R. H. J.; Tribo, A. R.; Yous, S.;
14 15		Stevens, R. C.; Weierstall, U.; Katritch, V.; Roth, B. L.; Liu, W.; Cherezov, V. Structural Basis
16 17 18		of Ligand Recognition at the Human MT1 Melatonin Receptor. <i>Nature</i> 2019, 569, 284–288.
20 21	(64)	Johansson, L. C.; Stauch, B.; McCorvy, J. D.; Han, G. W.; Patel, N.; Huang, XP.; Batyuk, A.;
22 23		Gati, C.; Slocum, S. T.; Li, C.; Grandner, J. M.; Hao, S.; Olsen, R. H. J.; Tribo, A. R.; Zaare, S.;
24 25 26		Zhu, L.; Zatsepin, N. A.; Weierstall, U.; Yous, S.; Stevens, R. C.; Liu, W.; Roth, B. L.; Katritch,
20 27 28		V.; Cherezov, V. XFEL Structures of the Human MT2 Melatonin Receptor Reveal the Basis of
29 30 31		Subtype Selectivity. Nature 2019, 569, 289–292.
32 33	(65)	Longo, P. A.; Kavran, J. M.; Kim, MS.; Leahy, D. J. Transient Mammalian Cell Transfection
34 35 36		with Polyethylenimine (PEI). Meth. Enzymol. 2013, 529, 227-240.
37 38 39	(66)	Cheng, Y.; Prusoff, W. H. Relationship Between the Inhibition Constant (K1) and the
40 41		Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction.
42 43		Biochem. Pharmacol. 1973, 22, 3099–3108.
44 45		
46 47		
48		
49		
50 51		
52		

## FIGURES, SCHEMES AND TABLES.



Ogerin:  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5 = H$ , X = N, n = 1

Figure 1. Chemical structure of 1 and three highlighted regions for SAR study.



Figure 2. Selectivity of the GPR68 PAM 71. Proton concentration response curves in the absence and presence of increasing concentrations of 1 at human GPR68 (A), 71 at human GPR68 (B), GPR4 (C), and GPR65 (D). Proton mediated G<sub>s</sub>-cAMP production was measured in HEK293T cells transiently transfected with GPR68, GPR4 or GPR65, and GloSensor cAMP plasmids. Results were normalized to the proton activity in the absence of modulator and represented means  $\pm$  SEM from a minimum of three

independent assays, each in quadruplicate. Curves were analyzed in Prism using the built-in four parameter logistic functions. (E) Selectivity of **71** over 48 common GPCRs, ion channels and transporters in radioligand binding assays. Values represent average binding affinity (pK<sub>i</sub>) from a minimum of 3 independent assays, each in triplicate. Targets with less than 50% inhibition at 10  $\mu$ M (in quadruplicate) are not shown. BZP for benzodiazepine receptor; DAT for dopamine transporter; DOR for delta ( $\delta$ ) opioid receptor; hERG for human ether-a-go-go related potassium channel; KOR for kappa ( $\kappa$ ) opioid receptor; MOR for mu ( $\mu$ ) opioid receptor; NET for noradrenaline transporter; PBR for peripheral benzodiazepine binding site; SERT for serotonin transporter. (F) Off-target agonist activity of **71** at human GPCRome. **71** was screened across the human GPCRome (318 GPCRs) for off-target agonist activity at 1  $\mu$ M using the PRESTO-Tango screening platform. Results (fold of basal) represent means of four replicates. Dopamine receptor D<sub>2</sub> with 100 nM quinpirole served as an assay control. Dash lines indicate an arbitrary cut-off line at 3x fold of basal.



Figure 3. Allosteric potentiation of proton activity by compound 71 at mouse GPR68.  $G_s$  GloSensor cAMP assays were carried out in HEK293T cells transiently transfected with mouse GPR68 as with human GPR68. Proton concentration responses were measured in the absence and presence of increasing concentrations of modulator. Results were normalized to proton activity in the absence of modulator and represented means  $\pm$  SEM from a minimum of three independent assays, each in quadruplicate. Curves were analyzed in Prism. Allosteric parameters are summarized in Table 5.



**Figure 4. Mouse pharmacokinetic profile of compound 71.** Compound concentrations were quantified in both plasma (red curve) and brain (blue curve) at 0.5, 1.0, and 2.0 h after a single 25 mg/kg IP administration. Compound concentrations in plasma and brain at each time point are average values from 3 test mice. Error bars represent ± SEM.

Scheme 1. Synthesis of **5-7** and **10**.



Reagents and conditions: (a) THF, 0 °C to rt, 48-67%; (b) Dioxane, reflux, 1 h, 56-96%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>,



Scheme 2. Synthesis of 13-15, 21, 16, 18-19, 22-29, 31-32 and 37-38.



alkyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, 85°C, 34-78%; (g) i. *n*-BuLi, THF, -78 °C, 30 min; ii. B(OMe)<sub>3</sub>, -78 °C, 1

h, then rt, overnight; iii. HCl (3 N), rt, 1 h, 26-57%; (h) 12, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, Dixoane / H<sub>2</sub>O = 5 : 3,

120 °C, Microwave, 20 min; (i) NaBH<sub>4</sub>, THF, 0 °C to rt, 23-97%.

Scheme 3. Synthesis of 41-54, 56-60 and 64-81.



Reagents and conditions: (a) Dioxane, reflux, 1 h, 75-96 %; (b) Pd(PPh<sub>3</sub>)<sub>4</sub>,  $K_2CO_3$ , Dixoane /  $H_2O = 5$ :

3, 120 °C, Microwave, 20 min, 16-99%.

# Table 1. Effects of modifications to the triazine core on allosteric activity.



Values represent means  $\pm$  SEM from a minimum of 3 independent assays, each in triplicate or quadruplicate.  $\Delta$  stands for the difference of Log( $\alpha\beta/K_B$ ) from that of 1, positive values indicated increased allosteric activity and negative values indicated reduced allosteric activity. Proton concentration-response curves are shown in Supplemental Figure 1. <sup>*a*</sup>The structure of 10 is shown.

## Table 2. Effects of modifications of the benzylmethanol moiety on allosteric activity.



$   \begin{array}{c}                                     $										
Compd	R <sup>3</sup>	$\mathbf{R}^4$	Log (a)	Log (β)	-Log (K <sub>B</sub> )	Log (αβ/K <sub>B</sub> )	Δ			
1	СН		$0.60 \pm 0.10$	$0.36 \pm 0.07$	$4.35 \pm 0.12$	$5.31 \pm 0.05$	0.00			
13	Н			<u> </u>	Inactive	I				
14	<u>`</u> Ме				Weak PAM					
15	O Me	Н			Weak PAM					
16	OH				Weak PAM					
18	NH <sub>2</sub>	-	$0.86 \pm 0.06$	$0.30 \pm 0.14$	$3.86 \pm 0.14$	$5.01 \pm 0.06$	-0.30			
19	NHMe		Weak PAM							
20		3-			Inactive					
21	Н	3- O Me			Inactive					
22		<b>3-</b> F	$0.59 \pm 0.30$	$0.27 \pm 0.13$	$4.01 \pm 0.13$	$4.86 \pm 0.06$	-0.45			
23		<b>4-</b> F	$0.64 \pm 0.13$	$0.24 \pm 0.13$	$4.58 \pm 0.06$	$5.46 \pm 0.07$	0.15			
24		<b>5-</b> F	$0.91 \pm 0.07$	$0.20 \pm 0.11$	$4.58 \pm 0.08$	$5.69 \pm 0.04$	0.38			
25		6-F	$1.15 \pm 0.14$	$0.35 \pm 0.16$	$3.69 \pm 0.12$	5.19 ± 0.03	-0.12			
26		4-Cl	$1.01 \pm 0.08$	$0.11 \pm 0.04$	$4.76 \pm 0.14$	$5.87 \pm 0.14$	0.56			
27		5-Cl	$1.20 \pm 0.11$	$0.09 \pm 0.02$	$4.49 \pm 0.19$	$5.78 \pm 0.09$	0.47			
28		6-Cl	$1.25 \pm 0.19$	$-0.12 \pm 0.03$	$4.43 \pm 0.20$	$5.56 \pm 0.04$	0.25			
29	СН	3- , 0	$0.40 \pm 0.12$	$0.30 \pm 0.06$	4.16 ± 0.16	4.86 ± 0.10	-0.45			

<b>30</b> <sup>44</sup>	4- >_0	$0.46 \pm 0.03$	0.14 ± 0.03	$4.12 \pm 0.11$	4.97 ± 0.11	-0.34			
31	5- , 0	0.61 ± 0.03	0.18 ± 0.06	3.99 ± 0.07	$4.77 \pm 0.04$	-0.54			
32	6- , 0	Weak PAM							
37	4- , 0	0.87 ± 0.11	0.10 ± 0.10	$4.37 \pm 0.04$	$5.34 \pm 0.03$	0.03			
38	4- >.0	0.56 ± 0.09	$0.27 \pm 0.07$	4.91 ± 0.12	$5.74 \pm 0.07$	0.43			

Values represent means  $\pm$  SEM from a minimum of 3 independent assays, each in triplicate or quadruplicate.  $\Delta$  stands for the difference of Log( $\alpha\beta/K_B$ ) from that of 1, positive values indicated increased allosteric activity and negative values indicated reduced allosteric activity. Proton concentration-response curves are shown in Supplementary Figure 1.

# Table 3. Effects of modifications of the benzylamine side chain on allosteric activity.



Compd	n	<b>R</b> <sup>5</sup>	Log (a)	Log (β)	-Log (K <sub>B</sub> )	$Log(\alpha\beta/K_B)$	Δ
1		Н	$0.60 \pm 0.10$	$0.36 \pm 0.07$	$4.35 \pm 0.12$	$5.31 \pm 0.05$	0.00
41		2-F	$0.98 \pm 0.15$	$0.31 \pm 0.10$	$4.27 \pm 0.10$	$5.56 \pm 0.07$	0.25
42		3-F	$0.70 \pm 0.13$	$0.33 \pm 0.10$	$4.52 \pm 0.10$	$5.55 \pm 0.05$	0.24
43		4-F	$1.09 \pm 0.30$	$0.36 \pm 0.02$	3.97 ± 0.33	$5.42 \pm 0.03$	0.11
44		2-Cl	$0.64 \pm 0.05$	$0.23 \pm 0.04$	$5.07 \pm 0.08$	$5.94 \pm 0.07$	0.63
45	-	3-Cl	$0.48 \pm 0.15$	$0.46 \pm 0.06$	4.97 ± 0.19	5.90 ± 0.05	0.59
46		4-Cl	$0.49 \pm 0.09$	$0.41 \pm 0.07$	$5.22 \pm 0.07$	$6.11 \pm 0.02$	0.80
47	-	2-CF <sub>3</sub>	$0.60 \pm 0.06$	0.31 ± 0.05	$5.05 \pm 0.10$	5.96 ± 0.05	0.65
48		<b>3-CF</b> <sub>3</sub>	0.64 ± 0.19	$0.32 \pm 0.13$	$5.11 \pm 0.12$	$6.07 \pm 0.04$	0.76
49		4-CF <sub>3</sub>	$0.78 \pm 0.05$	$0.30 \pm 0.06$	$5.03 \pm 0.08$	6.10 ± 0.06	0.79
50	1	2-Me	$0.54 \pm 0.15$	$0.33 \pm 0.14$	$4.70 \pm 0.08$	$5.57 \pm 0.08$	0.26
51		3-Me	$0.92 \pm 0.16$	$0.25 \pm 0.09$	$4.40 \pm 0.18$	$5.57 \pm 0.08$	0.26
52		4-Me	$0.90 \pm 0.06$	$0.32 \pm 0.05$	$4.38 \pm 0.17$	$5.60 \pm 0.09$	0.29
53		2-OMe	$0.98 \pm 0.17$	$0.06 \pm 0.01$	$3.99 \pm 0.20$	$5.03 \pm 0.04$	-0.28
54		3-OMe	$0.89 \pm 0.18$	$0.23 \pm 0.06$	4.11 ± 0.18	$5.22 \pm 0.05$	-0.09
5544		4-OMe	$0.78 \pm 0.11$	$0.49 \pm 0.10$	$3.34 \pm 0.13$	$4.61 \pm 0.09$	-0.70
56		4-OEt	$0.81 \pm 0.05$	$-0.01 \pm 0.05$	$4.77 \pm 0.03$	$5.57 \pm 0.04$	0.26
57		4-O <sup>i</sup> Pr	$0.53 \pm 0.09$	$0.17 \pm 0.12$	$4.99 \pm 0.09$	$5.69 \pm 0.03$	0.38
58		4- ×0	$0.67 \pm 0.07$	$0.04 \pm 0.05$	5.07 ± 0.12	5.77 ± 0.04	0.46
59		4-OPh	$0.95 \pm 0.09$	$0.00 \pm 0.04$	5.19 ± 0.14	$6.14 \pm 0.10$	0.83
60	0	Н	$0.72 \pm 0.14$	$0.40 \pm 0.09$	$3.92 \pm 0.10$	$5.04 \pm 0.06$	-0.27

<b>61</b> <sup>44</sup>	2		$0.88 \pm 0.15$	$0.24 \pm 0.10$	$4.50 \pm 0.21$	$5.62 \pm 0.07$	0.31
<b>62</b> <sup>44</sup>	3		$0.81 \pm 0.05$	$0.08 \pm 0.02$	$5.22 \pm 0.04$	$6.11 \pm 0.01$	0.80
<b>63</b> <sup>44</sup>	4		$0.62 \pm 0.05$	$0.21 \pm 0.05$	$5.52 \pm 0.12$	$6.35 \pm 0.08$	1.04
64	2		$0.83 \pm 0.14$	$0.03 \pm 0.06$	$5.00 \pm 0.11$	$5.90 \pm 0.05$	0.59
65	3	4-OPh	$1.19 \pm 0.12$	$-0.01 \pm 0.07$	$4.67 \pm 0.10$	$5.84 \pm 0.09$	0.53
66	4		$1.03 \pm 0.10$	$0.09 \pm 0.06$	$4.81 \pm 0.13$	$5.94 \pm 0.11$	0.62

Values represent means  $\pm$  SEM from a minimum of 3 independent assays, each in triplicate or quadruplicate.  $\Delta$  stands for the difference of Log( $\alpha\beta/K_B$ ) from that of 1, positive values indicate increased allosteric activity and negative values indicate reduced allosteric activity. Proton concentration response curves are shown in Supplementary Figure 1.

## Table 4. Effects of combined modifications on allosteric activity.



Compd	n	$\mathbf{R}^4$	<b>R</b> <sup>5</sup>	Log (a)	Log (β)	-Log (K <sub>B</sub> )	Log (αβ/K <sub>B</sub> )	
1		Н	Н	$0.60 \pm 0.10$	$0.36 \pm 0.07$	$4.35 \pm 0.12$	$5.31 \pm 0.05$	
67			2-F	$1.09 \pm 0.08$	$0.09 \pm 0.04$	$4.22 \pm 0.10$	$5.40 \pm 0.03$	;
68	1		<b>4-</b> F	$1.01 \pm 0.06$	$0.09 \pm 0.03$	$4.45 \pm 0.14$	$5.55 \pm 0.04$	
69			3-Me	$0.84 \pm 0.08$	$0.14 \pm 0.04$	$4.44 \pm 0.12$	$5.42 \pm 0.04$	- r
70	_		2-OMe	$1.12 \pm 0.08$	$-0.12 \pm 0.03$	$4.11 \pm 0.04$	$5.11 \pm 0.02$	,
71	_	6-F	4-OPh	$0.90 \pm 0.06$	$0.06 \pm 0.04$	$5.85 \pm 0.12$	$6.83 \pm 0.08$	;
72	2			$1.06 \pm 0.15$	$0.03 \pm 0.07$	$5.04 \pm 0.09$	$6.13 \pm 0.04$	
73	3	-	Η	$1.19 \pm 0.10$	$0.02 \pm 0.03$	$4.47\pm0.04$	$5.67 \pm 0.10$	)
74	4	-		$1.24 \pm 0.11$	$0.06 \pm 0.04$	$4.04 \pm 0.11$	$5.34 \pm 0.04$	
75	2	-	4-OPh	$1.14 \pm 0.09$	$-0.06 \pm 0.03$	$5.05 \pm 0.14$	$6.14 \pm 0.10$	,
76	3	-	1011	$1.15 \pm 0.11$	$0.01 \pm 0.05$	$4.94 \pm 0.11$	$6.10 \pm 0.11$	
77	2			$1.09 \pm 0.10$	$0.03 \pm 0.05$	$5.14 \pm 0.11$	$6.26 \pm 0.09$	)
78	3	-	Н	$1.03 \pm 0.07$	$0.01 \pm 0.04$	$5.35 \pm 0.06$	$6.38 \pm 0.05$	
79	4	5-Cl		$1.09 \pm 0.13$	$0.06 \pm 0.07$	$4.98 \pm 0.10$	$6.14 \pm 0.10$	)
80	1	1	4_0Ph	$1.05 \pm 0.09$	$0.03 \pm 0.03$	$4.70 \pm 0.14$	$5.78 \pm 0.11$	
81	2	1	4-011	$1.39 \pm 0.07$	$-0.04 \pm 0.08$	$4.59 \pm 0.18$	$5.87 \pm 0.14$	-

Values represent means  $\pm$  SEM from a minimum of 3 independent assays, each in triplicate or quadruplicate.  $\Delta$  stands for the difference of Log( $\alpha\beta/K_B$ ) from that of 1, positive values indicate increased allosteric activity and negative values indicate reduced allosteric activity. Proton concentration response curves are shown in Supplementary Figure 1.

Table 5. Allosteric par	rameters of select	ed PAMs at mouse	<b>GPR68.</b>
-------------------------	--------------------	------------------	---------------

Compd	Log(a)	Log(β)	-Log(K <sub>B</sub> )	$Log(\alpha\beta/K_B)$	Δ	
1	0.80 ± 0.11	0.04 ± 0.05	4.13 ± 0.09	4.97 ± 0.02	-0.34	
46	$1.41 \pm 0.08$	-0.0 2± 0.06	$4.30 \pm 0.03$	5.68 ± 0.05	-0.43	
63	0.91 ± 0.18	0.08 ± 0.03	4.91 ± 0.17	5.89 ± 0.02	-0.40	
71	$1.26 \pm 0.14$	0.09 ± 0.03	5.12 ± 0.19	6.46 ± 0.05	-0.43	
77	$1.06 \pm 0.12$	0.13 ± 0.09	$4.72 \pm 0.02$	5.92 ± 0.02	-0.34	
78	0.99 ± 0.06	0.13 ± 0.06	$4.86 \pm 0.08$	5.98 ± 0.04	-0.40	
78	0.99 ± 0.06	$0.13 \pm 0.06$	$4.86 \pm 0.08$	$5.98 \pm 0.04$	-0.40	

Values represent means  $\pm$  SEM from a minimum of 3 independent assays, each in quadruplicate.  $\Delta$  stands for the difference of Log( $\alpha\beta/K_B$ ) from the corresponding values at human GPR68 (Tables 1-4), positive values indicate increased allosteric activity and negative values indicate reduced allosteric activity. Proton concentration response curves are presented in Figure 3 and Supplementary Figure 7.

ACS Paragon Plus Environment

## **Table of Contents Graphic:**

